---
document_datetime: 2023-09-21 19:44:07
document_pages: 71
document_pathfilename: www.ema.europa.eu/en/documents/variation-report/mabthera-h-c-165-ii-150-epar-assessment-report-variation_en.pdf
document_name: mabthera-h-c-165-ii-150-epar-assessment-report-variation_en.pdf
version: success
processing_time: 115.7989213
conversion_datetime: 2025-12-22 13:01:27.667269
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

31 January 2019 EMA/206826/2019 Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

## MabThera

International non-proprietary name: rituximab

Procedure No. EMEA/H/C/000165/II/0150

## Note

Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure..............................................                                   | 5                                                                                                         |
|----------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------|
| 1.1. Type II variation ..................................................................................................5 |                                                                                                           |
| 1.2. Steps taken for the assessment of the product                                                                         | ........................................................5                                                 |
| 2. Scientific discussion................................................................................                   | 6                                                                                                         |
| 2.1. Introduction                                                                                                          | ........................................................................................................6 |
| 2.2. Non-clinical aspects..............................................................................................8   |                                                                                                           |
| 2.2.1. Ecotoxicity/environmental risk assessment...........................................................8               |                                                                                                           |
| 2.2.2. Conclusion on the non-clinical aspects                                                                              | .................................................................8                                        |
| 2.3. Clinical aspects                                                                                                      | ....................................................................................................8     |
| 2.3.1. Introduction......................................................................................................8 |                                                                                                           |
| 2.3.2. Pharmacokinetics                                                                                                    | ..............................................................................................9           |
| 2.3.3. Pharmacodynamics..........................................................................................          | 10                                                                                                        |
| 2.3.4. PK/PD modelling                                                                                                     | ............................................................................................. 12          |
| 2.3.5. Discussion on clinical pharmacology...................................................................              | 12                                                                                                        |
| 2.3.6. Conclusions on clinical pharmacology.................................................................               | 12                                                                                                        |
| 2.4. Clinical efficacy                                                                                                     | .................................................................................................. 12     |
| 2.4.1. Dose response study(ies) .................................................................................          | 12                                                                                                        |
| 2.4.2. Main study - Study ML22196............................................................................              | 13                                                                                                        |
| 2.4.3. Discussion on clinical efficacy............................................................................         | 39                                                                                                        |
| 2.4.4. Conclusions on the clinical efficacy ....................................................................           | 42                                                                                                        |
| 2.5. Clinical safety                                                                                                       | .................................................................................................... 42   |
| 2.5.1. Discussion on clinical safety..............................................................................         | 58                                                                                                        |
| 2.5.2. Conclusions on clinical safety ............................................................................         | 58                                                                                                        |
| 2.5.3. PSUR cycle                                                                                                          | ..................................................................................................... 58  |
| 2.6. Risk management plan                                                                                                  | ....................................................................................... 58                |
| 2.7. Update of the Product information........................................................................             | 66                                                                                                        |
| 2.7.1. User consultation ............................................................................................      | 66                                                                                                        |
| 3. Benefit-Risk Balance.............................................................................                       | 66                                                                                                        |
| 3.1. Therapeutic Context                                                                                                   | ........................................................................................... 66            |
| 3.1.1. Disease or condition                                                                                                | ........................................................................................ 66               |
| 3.1.2. Available therapies and unmet medical need.......................................................                   | 67                                                                                                        |
| 3.1.3. Main clinical studies.........................................................................................      | 67                                                                                                        |
| 3.2. Favourable effects..............................................................................................      | 67                                                                                                        |
| 3.3. Uncertainties and limitations about favourable effects.............................................                   | 67                                                                                                        |
| 3.4. Unfavourable effects...........................................................................................       | 68                                                                                                        |
| 3.5. Uncertainties and limitations about unfavourable effects                                                              | ......................................... 68                                                              |
| 3.6. Effects Table......................................................................................................   | 68                                                                                                        |
| 3.7. Discussion on the benefit-risk assessment.............................................................                | 69                                                                                                        |
| 3.7.1. Importance of favourable and unfavourable effects..............................................                     | 69                                                                                                        |
| 3.7.2. Balance of benefits and risks                                                                                       | ............................................................................ 69                           |
| 3.8. Conclusions.......................................................................................................    | 69                                                                                                        |

<div style=\"page-break-after: always\"></div>

4. Recommendations  ................................................................................. 70

5. EPAR changes ....................................................................................... 71

<div style=\"page-break-after: always\"></div>

## List of abbreviations

| ABSIS   | autoimmune bullous skin disorder intensity score antibody                                                            |
|---------|----------------------------------------------------------------------------------------------------------------------|
| ADA     | anti-drug antibody/anti-rituximab                                                                                    |
| AE      | adverse event                                                                                                        |
| AI      | autoimmune                                                                                                           |
| BMI     | body mass index                                                                                                      |
| BSA     | body surface area                                                                                                    |
| CI      | confidence interval                                                                                                  |
| CLL     | chronic lymphocytic leukemia                                                                                         |
| CR      | complete remission                                                                                                   |
| CRF     | case report forms                                                                                                    |
| CRoff   | CR off corticosteroid/prednisone therapy                                                                             |
| CRon    | CR on corticosteroid therapy                                                                                         |
| CSR     | clinical study report                                                                                                |
| Dsg     | desmoglein                                                                                                           |
| ELISA   | enzyme linked immunosorbent assay                                                                                    |
| FDA     | US Food and Drug Administration                                                                                      |
| GI      | gastrointestinal                                                                                                     |
| GPA     | granulomatosis polyangiitis                                                                                          |
| HLA     | human leukocyte antigen                                                                                              |
| ICD     | International Statistical Classification of Diseases and Related Health Problems, 10th revision, German modification |
| iDMC    | independent data monitoring committee                                                                                |
| IRR     | infusion-related reaction                                                                                            |
| ITT     | intent to treat                                                                                                      |
| IV      | intravenous                                                                                                          |
| MMF     | mycophenolate mofetil                                                                                                |
| MPA     | microscopic polyangiitis                                                                                             |
| NHL     | non-Hodgkin's lymphoma                                                                                               |
| PBRER   | periodic benefit risk evaluation report                                                                              |
| PDAI    | pemphigus disease activity score                                                                                     |
| PF      | pemphigus foliaceus                                                                                                  |
| PML     | progressive multifocal leukoencephalopathy                                                                           |
| PR      | partial remission                                                                                                    |
| PK      | pharmacokinetic                                                                                                      |
| PT      | preferred terms                                                                                                      |
| PV      | pemphigus vulgaris                                                                                                   |
| PVAS    | pemphigus vulgaris activity score                                                                                    |
| RA      | rheumatoid arthritis                                                                                                 |
| SAE     | serious adverse event                                                                                                |
| SAP     | statistical analysis plan                                                                                            |
| SCE     | summary of clinical efficacy                                                                                         |
| SCS     | summary of clinical safety                                                                                           |
| SE      | standard error                                                                                                       |
| SOC     | system organ class                                                                                                   |
| TPMT    | thiopurine methyltransferase                                                                                         |
| UK      | United Kingdom                                                                                                       |
| US      | United States                                                                                                        |
| USPI    | US Prescribing Information                                                                                           |

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Type II variation

Pursuant to Article 16 of Commission Regulation (EC) No 1234/2008, Roche Registration GmbH submitted to the European Medicines Agency on 2 March 2018 an application for a variation.

The following variation was requested:

| Variation requested   | Variation requested                                                                                                            | Type    | Annexes affected   |
|-----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a               | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I and IIIB         |

Extension of indication to include the treatment of patients with moderate to severe pemphigus vulgaris (PV) for MabThera; as a consequence, sections 4.1, 4.2, 4.3, 4.4, 4.8 and 5.1 of the SmPC are updated. The MAH provided data from a phase III, randomized, controlled, multicenter, open-label study (Study ML22196) evaluating rituximab treatment plus short-term, low dose prednisone treatment compared to long-term, standard dose prednisone treatment as first-line treatment in patients with moderate to severe pemphigus. The Package leaflet is updated accordingly. Minor corrections are also proposed for the sake of accuracy and clarity. An updated RMP (v19.1) is also included in this submission.

The requested variation proposed amendments to the Summary of Product Characteristics and Package Leaflet and to the Risk Management Plan (RMP).

## Information on paediatric requirements

Not applicable

## Information relating to orphan market exclusivity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the applicant did not submit a critical report addressing the possible similarity with authorised orphan medicinal products because there is no authorised orphan medicinal product for a condition related to the proposed indication.

## Scientific advice

The applicant did not seek Scientific Advice at the CHMP.

## 1.2. Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

Rapporteur:

Sinan B. Sarac

Co-Rapporteur:

Paula Boudewina van Hennik

<div style=\"page-break-after: always\"></div>

| Timetable                                            | Actual dates      |
|------------------------------------------------------|-------------------|
| Submission date                                      | 2 March 2018      |
| Start of procedure:                                  | 31 March 2018     |
| CHMP Co-Rapporteur Assessment Report                 | 24 May 2018       |
| CHMP Rapporteur Assessment Report                    | 28 May 2018       |
| PRAC Rapporteur Assessment Report                    | 28 May 2018       |
| PRAC members comments                                | 6 June 2018       |
| Updated PRAC Rapporteur Assessment Report            | 8 June 2018       |
| PRAC Outcome                                         | 14 June 2018      |
| CHMP members comments                                | n/a               |
| Updated CHMP Rapporteur(s) (Joint) Assessment Report | 21 June 2018      |
| Request for supplementary information (RSI)          | 28 June 2018      |
| Submission of responses                              | 14 September 2018 |
| CHMP Rapporteur Assessment Report                    | 18 October 2018   |
| PRAC Rapporteur Assessment Report                    | 18 October 2018   |
| PRAC members comments                                | n/a               |
| Updated PRAC Rapporteur Assessment Report            | n/a               |
| PRAC Outcome                                         | 31 October 2018   |
| CHMP members comments                                | n/a               |
| Updated CHMP Rapporteur Assessment Report            | n/a               |
| Request for supplementary information (RSI)          | 15 November 2018  |
| CHMP Rapporteur Assessment Report                    | 20 December 2018  |
| PRAC Rapporteur Assessment Report                    | 20 December 2019  |
| PRAC members comments                                | n/a               |
| Updated PRAC Rapporteur Assessment Report            | n/a               |
| PRAC Outcome                                         | 17 January 2019   |
| CHMP members comments                                |                   |
| Updated CHMP Rapporteur Assessment Report            | 23 January 2019   |
| CHMP Opinion                                         | 31 January 2019   |

## 2. Scientific discussion

## 2.1. Introduction

Pemphigus vulgaris (PV) is a rare, serious and life-threatening AI blistering disease affecting the mucosa and skin, and there is a high unmet medical need for safer and more effective treatment options.  A comprehensive literature review of approximately 300 publications in PV conducted by the Applicant identified many small, uncontrolled studies and case reports in 788 patients that support the safe and effective use of rituximab in patients with severe or refractory PV.

<div style=\"page-break-after: always\"></div>

Due to the rarity of pemphigus, few prospective clinical trials are available and these are limited by the low numbers of patients studied and treatment arms that do not demonstrate statistically significant differences. Corticosteroids and, in some European countries, azathioprine are the only EU-approved treatments for patients with PV.  Systemic corticosteroids have been the mainstay of treatment for pemphigus patients since the 1950s based on limited and uncontrolled clinical data.  Similarly, the use of adjuvant immunosuppressant therapy, such as azathioprine, which has been approved alone and in combination with systemic corticosteroids, for the treatment of PV in the European Union for over 15 years, has been established in treatment guidelines in Europe despite the scarcity of well-designed randomized controlled studies, and evidence that adjuvant therapies have only a minimal steroid-sparing effect.

Based on the literature, chronic and/or high dose corticosteroid therapy alone results in an estimated remission rate of &lt; 30%.  Remission may be short lived. Serious and sometimes fatal AEs, resulting from immunosuppression due to long-term use of steroids, may occur.  Despite widespread use, there is no consensus on whether unapproved steroid-sparing agents are beneficial due to the scarcity of well-designed randomized controlled studies.  PV remains a serious life-threatening disease and given the unsatisfactory safety and efficacy profile of the existing approved therapies (corticosteroids and azathioprine), a major unmet medical need exists for safer and more effective novel, targeted mechanism-based treatment options for moderately to severely active PV.

Owing to its ability to deplete pathogenic B cells and reduce autoantibodies, rituximab has been successfully used for AI indications of RA and GPA/MPA.  Pemphigus patients develop autoantibodies to desmosomal cadherins. The mechanism that initiates the formation of these autoantibodies is presumed to involve loss of B cell tolerance to these self-antigens.  In PF, these autoantibodies target Dsg1; in PV, these autoantibodies target Dsg1 and Dsg3.  Circulating B cells produce these autoantibodies which bind to keratinocytes, inhibit cell-cell adhesion, and cause blister formation and inflammation in the skin and mucous membrane.  Beyond the reduction of autoantibodies contributing to disease, dysregulated B cells may further worsen the disease by secreting cytokines, co-stimulating T cells, and differentiating into memory B cells which contribute to persistent autoantibody production and relapsing disease.

In the last decade, there have been approximately 300 reports of rituximab use in 788 PV patients published as case reports and small uncontrolled clinical studies, especially in severe, recalcitrant disease.  These publications report on the successful use of rituximab in severe and refractory pemphigus due to its B cell-depleting effect.  Similar to RA and GPA/MPA, in PV patients treated with rituximab, it has been observed that profound peripheral B cell depletion occurs by 3 weeks and B cell reconstitution begins at approximately 6 months after rituximab treatment.  In addition, a dramatic decrease in anti-Dsg1 and anti-Dsg3 IgG antibodies was observed after rituximab treatment in 8 of 12 patients who achieved CR and CR in these patients was associated with blockage of B cell maturation, repopulation with naïve B cells and transitional B cells, delayed reappearance of memory B cells, and disappearance of desmoglein-specific IgG + B cells.

The Sponsor of Study ML22196 is Rouen University Hospital, France (Charles Nicolle Hospital-CHU-Hôpitaux de Rouen).  The Applicant provided the rituximab study drug and funding for the 12 month post-treatment follow-up period, but had no role in study design, study conduct, data collection, or publication of the results. Study database and supporting documents were transferred from the Sponsor to the Applicant in December 2016 after the study had been completed and database lock had occurred.

A MAH-sponsored double-blind, randomised, active-controlled Phase III Study WA29330 (PEMPHIX) is still ongoing.

The Applicant therefore seeks regulatory approval for rituximab in the following indication:

Rituximab is indicated for the treatment of adult patients with moderate to severe pemphigus vulgaris.

<div style=\"page-break-after: always\"></div>

## 2.2. Non-clinical aspects

No new clinical data have been submitted in this application, which was considered acceptable by the CHMP.

## 2.2.1. Ecotoxicity/environmental risk assessment

The pharmacologically active substance in MabThera, Rituximab (CAS 174722-31-7), is a recombinant immunoglobulin-G monoclonal antibody with a molecular mass of approximately 145 kD.

As an unaltered protein, Rituximab is predicted to be metabolised by regular proteinolysis in the patient and biodegraded in sewage treatment, as shown for other monoclonal antibodies. Thus, Rituximab is unlikely to result in a significant risk to the environment and therefore it is submitted that it does not need a formal ERA according to the EMA 2006 Guideline (corr. 2). This is acceptable to the CHMP.

## 2.2.2. Conclusion on the non-clinical aspects

It is agreed that due to the nature of the product and based on the data submitted in this application Rituximab is unlikely to result in a significant risk to the environment.

## 2.3. Clinical aspects

## 2.3.1. Introduction

The application consists of the data from a single multi-centre randomised controlled open-label trial with a 24-month treatment period and a 12-month follow-up period, comparing RTX and short-term 'low'-dose corticosteroids with long-term standard-dose corticosteroids in patients with newly diagnosed pemphigus vulgaris (PV) or pemphigus foliaceus. Most patients (had pemphigus vulgaris and the analyses focus on this population (denoted as ITT-PV), which is in line with the requested indication for pemphigus vulgaris only.

After completion of the clinical trial and database lock the data were transferred in December 2016 by the Sponsor-Investigator (Rouen University Hospital in France) to the applicant and MAH of MabThera (Roche) and re-analysed by a third party (Everest Clinical Research). The applicant stated that the study objectives and method of analysis for the primary endpoint were prospectively defined in the initial protocol and the sponsor's Statistical Analysis Plan.

The applicant had provided the study drug and funding for the 12-month follow-up period, and stated that they had no role in study design, study conduct, data collection, or publication of the results.

Currently another confirmatory study sponsored by the applicant is ongoing. Study WA29330 is a randomized (1:1), double-blind, double-dummy, active-comparator, parallel-arm, multi-center, superiority trial to evaluate safety and efficacy of rituximab compared with mycophenolate mofetil (MMF) in achieving sustained clinical remission (off prednisone for at least 4 consecutive months) at week 52, in adult patients with moderate-to-severely active pemphigus vulgaris. The planned enrolment of 132 patients in Study WA29330 was completed and primary analysis results are anticipated to be available Q4 2018/Q1 2019.

## GCP

The Clinical trials were performed in accordance with GCP as claimed by the applicant.

The applicant has provided a statement to the effect that clinical trials conducted outside the community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

<div style=\"page-break-after: always\"></div>

## 2.3.2. Pharmacokinetics

No pharmacokinetic or immunogenicity assessments were prospectively planned by the sponsor as part of the study ML22196 protocol or schedule of assessments. The applicant evaluated the frozen sera collected from rituximab-dosed patients and determined that it was not feasible to perform population pharmacokinetic analyses from the samples available from this study; most of the samples were outside the stability window based on available pharmacokinetic sample stability data, resulting in a very limited number of patient samples for which concentrations could be accurately quantified for inclusion in a population pharmacokinetic analysis (3.5 years). In addition, the information required for population pharmacokinetic analysis such as the actual date and time of blood sampling, the exact dose of rituximab administered (overall, in case of dosing interruption and/or relapse), and the actual date and time of drug administration were not collected on the patient Case Report Forms.

Rituximab concentrations were only measured in samples used for the measurement of serum anti-drug antibodies (ADAs), to help in the interpretation of the ADA data. No concentration data were provided.

Frozen serum samples were within the established stability for anti-drug antibody (ADA) analysis (7 years, 10 months), and the applicant assessed immunogenicity in the pemphigus vulgaris patient population.

For the analysis of rituximab concentrations in pemphigus vulgaris patient serum samples, validated ELISA was used. The calibration curve range was 2.5 - 160 ng/ml. The minimum dilution for neat human serum samples is 1/100, resulting in a minimum quantifiable concentration of 500 ng/ml. The accuracy and the precision were within acceptable ranges. No hook effect was observed (by using a high rituximab concentration level) and accuracy and linearity of dilution was determined to be acceptable. Stability of neat human serum samples was evaluated and within range for multiple freeze/thaw cycles, for 24 hours at room temperature, after long term storage at -20°C for four months and after long term storage at  -60°C or below for three years and six months.

An (updated) anti-rituximab antibody assay was developed with acceptable accuracy and precision. The relative sensitivity of the method for the evaluated positive control (rabbit polyclonal antirituximab antibodies) was approximately 1.42 ng/ml serum. Above this detection threshold, the assay can tolerate an approximate 590-fold excess of rituximab over anti-rituximab antibodies (evaluated for the positive control antibody during assay validation).

A patient was considered to have an ADA positive result when the baseline sample (i.e. prior to the first rituximab administration in the study) was negative or missing, and at least one sample post-baseline was positive and was classified as 'treatment-induced'. In patients where the baseline sample was positive, the patient was classified as 'treatment-enhanced', when at least one post baseline sample had an increase in titer of ≥0.6. In cases where the baseline sample was positive, but the post baseline samples increased by &lt;0.6, patients were classified as 'treatment unaffected'.

Baseline and at least one post-baseline sample were evaluable in 34 of the 38 pemphigus vulgaris patients in the rituximab + prednisone arm. Fourteen of the 34 patients (41%) were considered treatment-induced and 5 of 34 (15%) were considered treatment-enhanced. Therefore, the incidence of treatment-induced/enhanced in pemphigus vulgaris patients was 19 of 34 patients (55.9%). ADAs were generally transitory, with positive titers ranging from 1 to 4.31.

Rituximab concentrations were reported in one publication in the pemphigus vulgaris patient population (Schmidt et al. 2009). The pharmacokinetics of rituximab was characterized in 11 patients (6 male and 5 female, aged 27 - 70 years) with severe pemphigus vulgaris who were resistant to at least one previous therapy, not including rituximab. Rituximab was administered by infusions at a dose of 375 mg/m 2 at weekly intervals for a total of four doses. This is the same dose as recommended for patients with polyangiitis/microscopic polyangiitis patients. Patients also received immunosuppressant therapies

<div style=\"page-break-after: always\"></div>

including azathioprine, corticosteroids, and mycophenolate mofetil. In serum samples collected 3 months after the first rituximab infusion, the mean (s.d.) rituximab concentration was 22.9 (24.6) µg/ml and ranged from 4.8 to 89.2 µg/ml.

Using population pharmacokinetic analysis models previous developed for rheumatoid arthritis patients and granulomatosis with polyangiitis/microscopic polyangiitis patients, the rituximab concentrations at 3 months after first infusion from this publication were in agreement with those predicted for rheumatoid arthritis patients and granulomatosis with polyangiitis/microscopic polyangiitis patients (see figures below).

Figure PK 1. Comparison of simulated pharmacokinetic profiles and observed data (day 90) in pemphigus vulgaris patients who received 4 i.v. infusions of rituximab 375 mg/m 2 ; popPK model in rheumatoid arthritis patients (left figure) and polyangiitis/microscopic polyangiitis patients (right figure).

A.FullSimulatedPKProfile（First3Months)

<!-- image -->

## 2.3.3. Pharmacodynamics

## Mechanism of action

Rituximab is a chimeric murine/human monoclonal antibody that binds to B-lymphocyte antigen (CD20), a transmembrane protein present on B lymphocytes. The binding of rituximab to CD20 on B-lymphocytes promotes B cell lysis via a number of different possible mechanisms, including antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, and induction of apoptosis.

## Primary and secondary pharmacology

In study ML22196, pharmacodynamics measurements, i.e. level of CD19+ B-cells as a marker for the target CD20+ cells, and desmoglein (Dsg) 1 and 3 antibody titres, were performed for the first 37 patients. In the Safety-PV sample, pharmacodynamics measurements were available for n=16 in the rituximab group and 15 in the corticosteroid-only group.

One month after baseline, after two 1000 mg infusions in the rituximab group, the percentage of CD19+ B lymphocytes (of total lymphocytes) was on average 0.2% in the rituximab group and 14% in the corticosteroid-only group. It appears that the percentage of CD19+ B lymphocytes increases towards month 12, to approach baseline levels (Figure 6 below). At month 24, the percentage of CD19+ positive B lymphocytes was still low in the patients (n=15) from the rituximab treated group.

<!-- image -->

<div style=\"page-break-after: always\"></div>

Figure 6 Mean (95% Cl) CD-19+ Percentages by Visit (Safety)

<!-- image -->

Mnnih

Total lymphocytes include B and T cells. Cl = confidence interval Source:fpd004se

The baseline titres of anti-Dsg1 and anti-Dsg3 (Figure 8) decreased within 3 months to similar low levels in both groups (Figure 8). In the corticosteroid-only group, the titres of anti-Dsg3 started to increase again after 12 months, although they did not return to baseline level in 24 months. Anti-Dsg1 titres remained low over 24 months in both groups (not shown).

Figure 8 Dsg-3 Mean Titers (95% Cl) by Visit (Safety PV)

<!-- image -->

Cl = confidence interval

Source: fim002se

The pharmacodynamics results regarding sustained B-cell depletion and regarding sustained reduction of anti-desmoglein 1 and 3 are considered to be supportive for the mode-of-action of rituximab in pemphigus vulgaris. Anti-desmoglein 1 and 3 play a key role in the pathogenesis of pemphigus vulgaris.

There was no major difference between Rituximab arm (Rituximab + Low-Dose Prednisone) and High-Dose Prednisone treatment groups regarding the reduction of anti-desmoglein in the first 12 months of therapy. It is noted that high-Dose Prednisone treatment is known to be effective in PV. After 12 months, Rituximab + Low-Dose Prednisone was superior in reducing Dsg-3 titers. Although sample size for these measurements was low (N=37), sample size was pre-planned and seen the clear effect it is considered unlikely that a larger sample would change the results.

It is noted that mean percentages of CD19+ B cell may be a suboptimal presentation because distributions are expected to be skewed. Percentage of patients below detection limit over time (baseline, months 3, 6, 12, 18 and 24) could have been an alternative. Further, the number of patients in the corticosteroid group

<div style=\"page-break-after: always\"></div>

is very small. As the effect of rituximab on B-cells in auto-immune diseases is well established, the issue is not pursued.

## 2.3.4. PK/PD modelling

No PK/PD modelling has been applied.

## 2.3.5. Discussion on clinical pharmacology

The pharmacodynamics results regarding sustained B-cell depletion and regarding sustained reduction of anti-desmoglein 1 and 3 are considered to be supportive for the mode-of-action of rituximab in pemphigus vulgaris. Anti-desmoglein 1 and 3 play a key role in the pathogenesis of pemphigus vulgaris.

No pharmacokinetic data have been obtained in the submitted studies. In literature one study was described in this patient group, in which pharmacokinetic data was obtained 90 days after the first rituximab infusion.

Using the previous developed popPK models for rheumatoid arthritis (RA) patients and granulomatosis with polyangiitis/microscopic polyangiitis patients (GPA/MPA) did not indicate that the serum concentrations at day 90 in pemphigus vulgaris patients were different than those predicted in RA patients and GPA/MPA patients. Although these results may be expected, being all three autoimmune populations, it should be noted that the data in pemphigus vulgaris patients is very limited.

The majority of the patients developed ADAs (HACA), but seemed not to have a negative impact on efficacy (see clinical assessment).

Both rituximab as the comparator High-Dose Prednisone induced the reduction of auto-antibodies anti-desmoglein 1 and 3 to similar extent in the first 12 months of treatment. After 12 months, the reduction of these auto-antibodies was better maintained with rituximab, than with High-Dose Prednisone.

## 2.3.6. Conclusions on clinical pharmacology

No concerns have been identified with regard to the clinical pharmacology.

## 2.4. Clinical efficacy

Introduction

The basis of this application is the pivotal study, ML22196, where newly diagnosed patients with moderate to severe pemphigus are randomized to rituximab + low-dose corticosteroids (CS) or high-dose CS.

The goal of treatment is rapid disease control, thus, systemic CS have played a central role in the first-line. CS has been backbone of therapy in patients with pemphigus vulgaris (PV), and is usually very effective with regards to disease control. However, systemic CS comes at a cost, since side effects are common. Thus, in an  attempt  to  reduce  the  exposure  to  CS,  other  non-steroidal  immune-modulatory  agents,  such  as azathioprine and mycophenolate mofetil, have been used in combination with (low-dose) CS. However, despite the well-known use of CS sparring agents in the clinical setting, it is acknowledged that there has not been any prospective randomized clinical trial, where CS + a CS sparring agent showed positive efficacy.

## 2.4.1. Dose response study(ies)

Formal dose-response studies were not conducted but refer to the previous studies conducted in patients with RA. This is endorsed.

<div style=\"page-break-after: always\"></div>

The choice of the initial rituximab dose administered at 2 x 1000 mg IV, 2 weeks apart, was based on findings demonstrated in patients with RA where this regimen sustained peripheral B-cell depletion for approximately 6 to 9 months. The same has also been reported in PV patients treated with rituximab, where it  was  observed that B cell reconstitution begins at approximately 6 months after rituximab treatment (Mouquet et al. 2008).

Maintenance doses of 500 mg IV at 12 months (M12) and 18 months (M18) after the initial treatment was based on the Principal Investigator's previous published study in which the rate of relapse was observed to be approximately 30% after two years; with patients relapsing during the second year (mean (SD) time to relapse: 18.9 ± 7.9 months) (Joly et al. 2007). The two additional infusions at M12 and M18 were expected to prevent relapses during the second year of treatment. The Principal Investigator acknowledged that the 500 mg dose of rituximab used for maintenance had not been formally studied although it was similar to the maintenance dose used in ANCA associated vasculitis (Guillevin et al. 2014). Patients could receive 1000 mg IV rituximab at the time of relapse (but no earlier than 16 weeks after the previous infusion), and the scheduled maintenance rituximab dose withheld, depending on the timing of the relapse.

## 2.4.2. Main study - Study ML22196

Title of Study: Comparison of Treatment with Anti-CD20 Monoclonal Antibody Rituximab (Mabthera®) in Combination  with  Short-Term  Systemic  Corticosteroid  Therapy  Compared  to  Long-Term  Systemic Corticosteroid Therapy in Patients with Pemphigus

Figure 1 Study Design for ML22196

<!-- image -->

CS = corticosteroid; D=day: IV =intravenous; M=month; mo=month; R =randomized

## Methods

## Study participants

## Inclusion Criteria

- 1) Patients between ≥18 and ≤80 years of age.
- 2) Written consent obtained from the patient (or a family member if the patient was unable to provide consent).
- 3) For women of childbearing potential, an effective method of contraception (e.g. intrauterine device, oral contraceptive pill)  was  required  during  treatment  and  for  a  year  following  discontinuation  of  rituximab treatment.
- 4) Newly diagnosed cases of PV or PF diagnosed based on all of the following items:
- Compatible or suggestive clinical signs (Martel and Joly 2001).

<div style=\"page-break-after: always\"></div>

- Histologic examination showing intraepidermal bullae including suprabasal or subcorneal detachment, in the presence of acantholytic cells.
- Direct immunofluorescence showing deposits of IgG and/or C3 on the keratinocyte cell membranes (mesh pattern).
- Patients solely treated with topical corticosteroid therapy (without systemic corticosteroid therapy or immunosuppressants) or having received less than one month of systemic corticosteroid therapy at a dose of ≤0.5 mg/kg/day prior to being diagnosed.

Note: the recent cases of pemphigus treated prior to the diagnosis by non-specific corticosteroid therapy (≤0.5 mg/kg/day) proven ineffective against pemphigus were not intentionally excluded because the practice of a short 'corticosteroid therapy trial' is quite common for undiagnosed oral erosions.

5) Current immunization status. The investigators confirmed the immunization status of all eligible patients and followed the national guidelines for the immunization plan in adults, ensuring a 28-day period between any vaccination and the first administration of rituximab.

Additionally, the following were considered as moderate pemphigus:

- a) Patients with non-severe oral involvement only based on Harman's criteria
- b) Patients with non-severe skin involvement only based on Harman's criteria.

c) Patients with mucocutaneous involvement including minimal skin involvement (&lt;5% of the body surface) and non-severe mucosal involvement based on Harman's criteria.

The following were considered as severe pemphigus:

- a) Patients with mucocutaneous involvement and significant skin involvement (&gt;5% of the body surface)

b) Patients with only mucosal involvement affecting at least two sites (e.g., oral and genital mucosa, oral and anal mucosa, oral and ear, nose and throat mucosa)

c) Patients with oral mucosal involvement only AND:

- -Weight loss of ≥3 kg related to dysphagia,
- -Severe mucosal involvement based on Harman's criteria:
- o Presence of at least 10 small discrete erosions, or
- o Confluent erosions of the oral mucosa, or
- o Generalized desquamative gingivitis with discrete erosions at other oral sites.

d) Pemphigus with only skin involvement considered severe based on Harman's criteria:

- -Presence of at least 20 erosive lesions or squamous/crusting lesions or bullous lesions, or
- -Extensive, confluent erosive lesions or squamous/crusting lesions.

## Exclusion Criteria

- 1) Previous pemphigus that has already been treated.
- 2) Pregnant or lactating woman.

<div style=\"page-break-after: always\"></div>

3) Known hypersensitivity to any one of the product compounds or to murine proteins, or previous history of allergic reaction to humanized monoclonal antibodies.

4) Unstable angina or advanced ischemic heart disease (recent extensive infarction &lt;3 months or post-MI cardiac failure)

5) Severe heart failure (New York Heart Association [NYHA] class III or IV), or severe, uncontrolled heart disease

6) Poorly controlled arrhythmia

7) Patients younger than 18 years of age or older than 80 years of age

8) Use of an immunosuppressant medication in the month prior to study enrollment.

9) Patients diagnosed with hepatitis B, or active or inactive hepatitis C. However, patients with hepatitis B antibodies resulting from a vaccination can be included.

10) Human immunodeficiency virus (HIV)-seropositive patient.

11) Bacterial, viral, fungal (excluding nail edge fungus) or mycobacterial infection, any other progressive infection, any significant event of infection requiring hospitalization or IV antibiotic treatment during the four weeks prior to screening, or an oral antibiotic treatment less than two weeks prior to the administration of rituximab.

12) History of deep tissue infection (fasciitis, deep-seated abscess, osteomyelitis, septic arthritis) in the year prior to the administration of rituximab.

13) Patients who have not provided their consent or who cannot be monitored regularly.

14) Active primary or secondary immune deficiency.

15) History of chronic or recurrent severe infection or any other underlying condition which predisposes the patient to severe infections.

16) Administration of a live vaccine in the 4 weeks prior to the administration of rituximab

17) Patients who have received immunosuppressive therapy (such as cyclosporine, mycophenolate mofetil, cyclophosphamide, azathioprine) or any other treatment that could potentially affect pemphigus lesions (disulone, IVIG, other biotherapies, plasma exchanges) in the month prior to enrollment in the trial.

18) Karnofsky index &lt;50%.

19) Previous treatment with rituximab or any other treatment leading to severe lymphocyte depletion (e.g., MabCampath).

20) Previous treatment with lymphocyte trafficking inhibitors (e.g., Tysabri).

21) Known severe chronic obstructive pulmonary disease (forced expiratory volume in 1 second  50% or grade 3 functional dyspnea)

Additionally, patients with paraneoplastic pemphigus were excluded from this study because of their very different disease progression and their prognosis depending strongly on the type of associated malignant tumor.

<div style=\"page-break-after: always\"></div>

## Treatments

For purpose of this study, rituximab was supplied and distributed by the applicant to the hospitals' pharmacies and was dispensed for the study patient through the pharmacy. Prednisone was obtained commercially by the patients themselves. The use of RTX in the study is identical to the use proposed in the SmPC for this indication. The aim of initial prednisone therapy in combination with rituximab was to control the patients' lesions until rituximab took effect.

After start in one of the two treatment arms the patients were assessed every 7 days to evaluate whether disease activity was 'in control'. This was defined according to the Consensus Statement on pemphigus endpoints [Murrell 2008] as: \"new lesions cease to form and established lesions begin to heal'. If disease activity was deemed 'in control' tapering was started [Murrell 2008] according to a predefined schedule. If after 4 weeks disease activity was not 'in control' the dose of corticosteroids remained the same up to another 4 weeks in the RTX arm or if disease activity was 'moderate'. Only in patients with 'severe' pemphigus who were in the corticosteroid arm the dose was increased to 2 mg/kg/day for up to another 4 weeks. If disease activity was severe and still uncontrolled after 8 weeks in any of the treatment arms, this was considered treatment failure, but the patient remained in the study for follow-up. If disease activity was moderate and still uncontrolled after 8 weeks, patients were treated as having 'severe' pemphigus.

Treatment with RTX consisted of two intravenous infusions of 1000 mg at day 1 (baseline) and day 15, administered at the hospital. Premedication with paradiphenhydramine antihistamine, paracetamol, and IV methylprednisolone was applied before each infusion. The third and fourth 'maintenance' infusions had a dose of 500 mg and were administered at 12 and 18 months after baseline (also see figure 1 above). In case of relapse, patients could receive 1000 mg RTX if the last infusion was longer than 16 weeks ago, and the next 'maintenance dose was then omitted.

The rationale for the initial RTX dosing (1000 mg 2 weeks apart) was based on the findings in patients with Rheumatoid Arthritis, where this dosing leads to B-cell depletion that is sustained for 6-9 months. This has also been found in a small (N=21) cohort of patients with pemphigus treated with RTX [Mouquet 2008]. These patients were treated with RTX in one cycle of four weekly infusions at a dosage of 375mg/m2 of body surface area, similar as in ANCA-positive vasculitis [Mabthera SmPC]. The rationale for the need of a 'maintenance' dose was based on the observation that about 30% of patients with pemphigus relapse after 2 years [Joly 2007]. The dose of 500 mg was supposed to prevent relapses but had not been studied in a dose-finding study, it had been applied in a similar way in ANCA-positive vasculitis [Guillevin 2014].

Treatment with prednisone was stratified according to disease severity and according to treatment group (Table 1). Tapering of corticosteroids for severe patients in the prednisone group will last 18 months in total, and for moderate patients in the RTX+prednisone group tapering will last 3 months in total (Table 1). The tapering schedule in the RTX group was based on earlier experience in the uncontrolled study of pemphigus patients (N=21) treated with RTX [Joly 2007]. Treatment with 'high dose' corticosteroids followed by slow tapering as soon disease activity is under control is regarded as standard of care [Murrell 2008].

<div style=\"page-break-after: always\"></div>

Table 1 Scheduled Oral Corticosteroid Treatment

<!-- image -->

Treatment of relapses was different in the two treatment groups.

Patients in the RTX and prednisone group received one infusion of RTX 1000 mg and prednisone was resumed or the prednisone dose was escalated. Subsequent infusions could occur no sooner than 16 weeks following the previous infusion and the next scheduled 'maintenance' infusion was left out. For example, if relapse occurred during the steroid taper or if relapse occurred after discontinuation of prednisone and before month 12, the patient received 1000 mg RTX at the time of relapse and the scheduled month 18 infusion of 500 mg RTX, but no infusion at month 12. If for example relapse occurred after discontinuation of prednisone and between month 12 and month 18, 1000 mg RTX was given at the time of relapse (no infusion at month 18), and if relapse occurred after month 18, the patient was treated with RTX 1000 mg at the time of relapse. In the event that a patient experienced more than one relapse, only the first relapse was treated with RTX.

Patients in the prednisone-only treated group resumed or escalated their prednisone dose. If relapse occurred during the prednisone taper, the prednisone dose was increased to a prior dose level that permitted disease control. If relapse occurred after prednisone withdrawal, prednisone was resumed at a dose of 0.3 mg/kg/day or 0.5 mg/kg/day depending on the severity of the relapse.

Relapse was defined as the appearance of 3 or more new lesions a month that did not heal spontaneously within 1 week or the extension of established lesions in a patient who had achieved disease control [Murrell 2008]. Presence of relapse was determined after physical examination at a study visit.

## Objectives

The protocol specified study objectives were:

- 1) To demonstrate that it was possible to control, and then to heal, the mucocutaneous lesions of patients with pemphigus vulgaris or pemphigus foliaceus, in spite of short-term systemic corticosteroid therapy, as a result of the use of rituximab.
- 2) To demonstrate that initial treatment with rituximab, repeated after 12 months and 18 months, helped achieve prolonged control of the mucocutaneous lesions caused by pemphigus, making it possible for a larger number of patients to achieve complete remission without corticosteroid therapy at 24 months and 36 months after the start of treatment, compared to a standard regimen of systemic corticosteroid therapy.

<div style=\"page-break-after: always\"></div>

3) To demonstrate that the rituximab + prednisone treatment regimen was well tolerated with fewer side effects of systemic corticosteroid therapy. An extended follow-up period (up to 10 years) was to be carried out to ensure the long-term absence of side effects (e.g., lymphoma, progressive multifocal leukoencephalopathy [PML]).

4) To monitor the changes in biological and immunological parameters during treatment, namely those related to activation of B lymphocytes specifically directed against desmogleins 1 and 3. In particular: the titer, isotype, and specificity of anti- Dsg-1 and anti-Dsg-3 antibodies, the total number of B lymphocytes and the number of Dsg-1-specific B lymphocytes, Dsg-3-specific B lymphocytes, B cell repertoire, Dsg-1specific B-cell repertoire, and Dsg-3-specific B-cell repertoire were to be monitored.

Any differences between the protocol-specified objectives and those included in the Applicant's analyses and any objectives not carried out are presented in the section 'Conduct of the study'.

## Outcomes/endpoints

## Primary Endpoint

The primary endpoint was the evaluation of complete remission (complete epithelialization and absence of new  and/or  established  lesions)  at  Month  24  without  CS  therapy  for  at  least  two  months  ('complete remission  off  therapy'  according  to  the  'Consensus  Treatment  Definitions  of  Disease  Endpoints  and Therapeutic Responses for Pemphigus' [Murrell et al. 2008]).

## Secondary Endpoints

- 'Severe' and 'moderate' relapses at Month 24. Relapse defined as 3 or more new lesions per month that do not heal spontaneously  within a week or extension of established lesions in a patient who has achieved disease control. The definitions of 'severe' and 'moderate' relapse correspond to the protocol definitions  of  severe  and  moderate  pemphigus,  but  in  addition,  if  a  relapse  remained  uncontrolled despite 4 weeks of prednisone dose increases to 0.5 mg/kg/d, the relapse was considered severe.
- Complete remission at Month 24 with minimal CS treatment ('Complete remission on minimal therapy,' defined according to the Consensus Statement (Murrell et al. 2008) as a dose of prednisone ≤ 10 mg/day).
- Total mean cumulative dose of prednisone up to Month 24.
- The  mean duration  of  complete  remission  (healing  of  the  mucocutaneous  lesions)  without  general corticosteroid therapy at Month 24.
- The number of SAEs, including death, attributable to the corticosteroid therapy and/or rituximab.
- Quality-of-life scores (Skindex-France [Chren et al. 1997, Leplege et al. 2003] herein referred to as 'Skindex')  and  Dermatology  Life  Quality  Index  (DLQI)  [Basra  et  al.  2015])  at  baseline  (start  of treatment) and Months 3, 6, 9, 12, 18 and 24. Patient reported outcomes of health-related quality of life were assessed using the Skindex- France and DLQI Skin Diseases, both of which are validated and reliable patient self-reported measures available in French that measure the impact of skin disease on the psychological well-being, social functioning and everyday activities of the patients. The recall period for the Skindex-France is the previous week and consists of eight scales, which address the following: cognitive  effects,  social  effects,  depression,  fear,  embarrassment,  anger,  physical  discomfort,  and physical limitations. The DLQI refers to the past 7 days and includes 10 questions addressing symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. A lower score for both the Skindex-France and DLQI indicates better quality of life.

## Additional Endpoints

The following additional pharmacodynamic, safety and efficacy endpoints, including exploratory endpoints, were evaluated:

<div style=\"page-break-after: always\"></div>

- Percentages of CD-19+ peripheral B-lymphocytes at baseline and post-baseline study visits in the first 37 patients randomized in the study.
- Retrospective anti-drug antibody (ADA) measurements at baseline, D180, D365, and D545 study visits in patients treated with rituximab + prednisone.
- Measurements of anti-Dsg-1 and -Dsg-3 pathogenic antibodies at baseline and post-baseline study visits.
- Non-serious AEs related to trial drugs with information collected in the study CRFs, the reported grade of intensity (Common terminology criteria for adverse events [CTCAE] v4) and the timing.
- Numbers of relapses (either 'severe' or 'moderate') at Month 36 (± 4 months), for patients who achieved complete remission off prednisone therapy at Month 24 (primary endpoint).

## Data management

CRFs were used for the prospective data collection. A Clinical Research Associate delegated by the sponsor-investigator (CHU Rouen) performed monitoring which included validation of 100% of critical data in all patients. Due diligence site visits of the Sponsor site and select investigator sites (for sites with high patient enrollment) were conducted by the Applicant in 2017. Overall, the findings at the site visits provided supportive evidence that the study was conducted according to GCP.

## Sample size

The number of patients estimated for inclusion in the study by the Sponsor was 45 patients per treatment arm, for a total number of 90 patients. This number was calculated according to the primary assessment criterion (number of patients in complete remission, tapered off any CS treatment for at least 3 months, during the evaluation at M24) as described in the Protocol v3.

## Randomisation

Randomization was centralized and performed by the Biostatistical Unit at the Rouen University Hospital. After determining eligibility (verifying inclusion criteria and signing the consent form), the patients were randomized 1:1 to receive one of the two treatments (rituximab + prednisone or prednisone) and were stratified  by  severity  of  pemphigus  (moderate  or  severe).  Within  each  strata  (moderate  or  severe), randomization to each treatment arm was conducted using permuted blocks of size 4.

## Blinding (masking)

Not applicable; this was an open-label study.

## Statistical methods

## Analysis populations

The intention-to-treat population consisted of all randomized patients, even if no study treatment was received. The primary population for efficacy was the ITT population of all patients being diagnosed as having pemphigus vulgaris (ITT-PV). Patients with pemphigus foliaceus (PF) were analysed within the total ITT population for the primary outcome only. The safety population consisted of all (PV and PF) patients who were treated with either rituximab or protocol-specified prednisone treatment.

The primary analysis of the primary endpoint is a chi square test (or Fisher exact test in case expected cell frequencies are below 5). The Sponsors regarded patients who withdrew due to inefficacy of treatment, to a serious side event threatening the vital prognosis, enrolled by mistake and thus excluded, lost-to-follow-up, or died during the study, as treatment failures. The Applicant regarded patients without an assessment at month 24 for any reason and patients who withdrew early even if they had follow-up data at month 24 as

<div style=\"page-break-after: always\"></div>

treatment failures. The Applicant added a Cochran-Mantel-Haenszel test for gender difference and a log binomial regression to adjust for gender and PDAI.

An analysis using the original definition (complete remission without prednisone therapy for at least three months) was performed as well.

Continuous outcomes were analysed using a t-test (if normality was not violated) or a Mann-Whitney U test otherwise. Chi square test (or Fisher exact test in case expected cell frequencies are below 5)were used for binary variables.

For each patient in complete remission without oral corticosteroid therapy at Month 24, the average period during which the patient was in complete remission off corticosteroid therapy will be evaluated. Only data where the duration is at least 2 months will be analysed. This will be confirmed through either a yes answer for the CRF item 'In complete remission and no longer receiving oral corticosteroid therapy for 3 months', or by confirming that patient is in remission and no longer receiving prednisone at both Month 22 and Month 24 visits. The average period will also be assessed for patients off corticosteroid therapy for 3 months, using only the CRF item.

To this end, the time duration will be calculated by using, as date of origin: the date of complete remission without corticosteroid therapy, and as end date, the last date of visit during which no relapse was noted without intake of corticosteroid therapy. Since prednisone dose is not reported at Day 1, the dose reported at Day 7 will be assumed to apply from Day 1 to the day before Day 7. Similarly, the dose reported at subsequent visits will be assumed to apply from the previous visit to the day before the reporting visit. For missing dose, the last previous non-missing dose will be carried forward (LOCF method), except after the last reported nonzero dose.

## Results

## Participant flow

<!-- image -->

<div style=\"page-break-after: always\"></div>

In the ITT sample up to 24 months, there were n=2 (4%) withdrawals in the rituximab treatment group and n=13 (30%) withdrawals in the corticosteroid-only treatment group. Most of the withdrawals in the latter group were because of adverse events (n=8) or because of lack of effectiveness/relapse (n=4). The visit at month 36 (figure 1) was added by amendment, when a number of patients already had passed month 36. Month 36 visits could be assessed in 71% of patients and was assessed post-hoc 22% and remained missing in 7% (Table 2).

Table 2

## SummaryofAnalysisPopulationsinStudyML22196

|                      | Rituximab+Prednisone (N-46)   | Prednisone (N-44)   |
|----------------------|-------------------------------|---------------------|
| intent-to-treat-     | 46(100.0%)                    | 44(100.0%)          |
| Safetya              | 46 (100.0%)                   | 44 (100.0%)         |
| Receivedrituimab\"    | 46(100.0%)                    | 0                   |
| Received prednisone\" | 0                             | 44 (100.0%)         |
| Intent-to-treat Pv   | 38 (82.6%)                    | 36 (81.8%)          |
| Safety PV            | 38(82.6%)                     | 36(81.8%)           |
| Received rituimab*   | 38(82.6%)                     |                     |
| Receivedprednisone   | 0                             | 36 (81.8%)          |

PV-pemphigusvulgaris

Patentswith a diagnosis ofPV

Patientswith a diagnosisofPVor pemphigus foliaceus

Source:ML22196CSRTable8

In the ITT-PV sample , n=38 patients were allocated to the rituximab group and n=36 were allocated to the corticosteroid-only group. In the rituximab group, one patient withdrew from treatment (because of pregnancy), but all n=38 patients completed the month 24 visit. In the corticosteroid-only group, n=12 (33%) patients withdrew from treatment, while n=30 (83%) completed the month 24 visit. The number and reasons for withdrawal in the ITT-PV sample are shown in Table 3.

Table 3

## Reasons for Protocol Withdrawal (ITT-PV Populatlon)

<!-- image -->

|                                                                      |       |                | All Fawienno (-74)   |
|----------------------------------------------------------------------|-------|----------------|----------------------|
| Waehdrmalo                                                           | 2.641 | .111           | 19.64                |
| Peasen:                                                              |       |                |                      |
|                                                                      | 0.001 | 0.001          | 0.011                |
| Lons Te Tollow-Qp                                                    |       | 2.8            |                      |
| Hichew Conuene                                                       |       | 0.001          | 8.991                |
|                                                                      | 0.011 | 19.111 口 0.011 | 10.041 口 9.041       |
|                                                                      | 0.011 | 0.041          | 0.041                |
|                                                                      | 0.041 |                |                      |
| Oehns                                                                |       |                | 5.411 1.401          |
| Jhnnee O! Sigallleetiw Hllestlyom!                                   | 0.011 | H              | 1.191                |
| Lonh 9l Dhrepanelo Pareene. ry log Senurolled ty Sunple Conloothrepy | 4098  |                |                      |
|                                                                      | 0.01  | H              | 1                    |

<!-- image -->

First Patient Entered: 15 May 2010

Last Patient Entered: 07 December 2012

<div style=\"page-break-after: always\"></div>

## LPLV: 22 March 2016

The Principal Investigator was Prof. Pascal Joly. Twentyfive other primary investigators belonging to the Bullous Group of the French Dermatology Society enrolled patients. France (26 centers)

## Conduct of the study

## Protocol Amendments

There were a total of 13 protocol amendments; the first 2 amendments occurred before the first patient was enrolled under Protocol v3. Table 4 lists major changes to the protocol. In protocol v12 dated 31 March 2014, clinical follow-up was extended to 36 months; Due to the fact that the extension of clinical follow-up took place late in the study (M24 LPLV for the primary endpoint was 04 December 2014), the additional visit was not done at M36 for all patients. Some patients had a follow-up visit after M36 which recorded their clinical status at the time of the visit, and their clinical status at M36 was retrospectively assessed. Extended follow-up of 10 years, which was included in the objectives in Protocol v14, was not performed.

Of importance, in Protocol v13 dated 25 June 2015, the definition of complete remission off prednisone was modified to reflect the updated clinical guidelines on duration of complete remission off of CS (Murrell et al. 2008). Thus, the primary efficacy endpoint was changed from CRoff CS for at least 3 months at M24 to CRoff CS for at least 2 months at M24.

## Protocol-Specified Study Objectives

The protocol specified objectives included the intent to monitor changes in biological and immunological parameters during treatment, namely those related to activation of B lymphocytes specifically directed against Dsg-1 and Dsg-3. This objective was considered to be exploratory by the Applicant and for the purposes of this CSR analyses were limited to Dsg-1 and Dsg-3 antibody levels.

## Comparison of Protocol-Specified and DAP-Specified Study Endpoints and Analyses

A number of secondary endpoints were specified in the Sponsor's Protocol v14.

The key changes were:

- Quality of life (QoL) was assessed at additional timepoints compared to those specified in the Protocol v14. QoL was assessed with Skindex-France and DLQI at Months 3, 6, 9, 12, 18 and 24. The following protocol-specified secondary endpoints were not included in the Applicant's analyses:
- The number of patients with complete healing of their mucocutaneous lesions six months after the start of treatment.
- The number of patients with incomplete remission off treatment at M24.
- The  number  of  patients  in  complete  remission,  who  continued  on  minimal  corticosteroid  therapy (prednisone  10 mg/day) at M36 (+/- 4 months), or received multiple courses of corticosteroid therapy following one or more relapses.
- The number of patients in complete remission off treatment at M36 (+/- 4 months). The Applicant also performed analyses of the following additional endpoints not included in the protocol (Applicant DAP):
- Pharmacodynamic counts and percentages of CD-19+ B-Lymphocytes at Baseline and post-Baseline study visits.
- Retrospective measurements of ADA at Baseline, D180, D365, and D545 study visits.
- Measurements of anti-Dsg-1 and -Dsg-3 antibodies at Baseline and post-Baseline study visits.

<div style=\"page-break-after: always\"></div>

- For side effects (AEs related to trial drugs with information collected in the study CRFs), the reported grade of intensity (CTCAE version 4) and the timing.
- Numbers of relapses (either 'severe' or 'moderate') at M36 (± 4 months), for patients who achieved complete remission off CS therapy for at least 2 months at M24.

The Applicant also presented an analysis of selected AEs of rituximab (infections and IRRs) and infections. Additionally, the primary analysis was stratified by gender to assess gender effect on response; this was not part of the sponsor's analysis plan.

## Differences in Analysis between the Sponsor SAP and the Applicant DAP

The Sponsor's SAP v3 states that all analyses will be performed for the ITT population. In the Applicant's DAP, all analyses were performed for the PV population; only selected analyses were done for the ITT population.

Table 4

## Summary of Select Key Changes to the Protocol

<!-- image -->

| Document Vemion, Date                                                                    | Summary of Key Change                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Rationale for Change                                                                                                                 |
|------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------|
| ProtocoV03 29 Januany 2009 The tnt protetei verion lubmioed le tihe French Heaim Aumorty | Duouo o Suued wogeuoyu Joebg Pepdn neuroiogkal eymptoms torpossbiePML Added meatment infomation for mid,modenate.and eevere infution reactions Exclvsion ertena were modled to include hintory of alergic reacton to monocional antbode, clase ll NmHA hean talun beatment witnin 4 weelus prior to study. history ef deep bstue intecbon within 1 yearpnor to udy.ctve pnmary or econdary Lmmune eelciency,Nstory e chvonk or retument nfecton pdminiotrabon of lve vaccine wth 4 weip pror to otudy. pnevovl beatment wien Rtuimab cr any teatment leeding to Hevere nhphocyle daplhton,pnevioun treatment wh ymphocy taflciing inhbtos,and severe chrenie cbstuetve puimenary dsease | Specilcatom requHtnd by AFFSAPS Specilcatom requested by AFFSAPS Specirlcatons requested by AFFSAPS Specilcatonsrequented by AFFSAPS |
|                                                                                          | The duration cf he mt and mecond Rieuximab intusions were changed fom 2 hours 15 minutes to 4 houns 30 mnuies The douage for me fnt and second Rueusiemsb induaione were puoinu dhugooi owg c uongu bu oos omgwo peouou                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | increamd initial doange requined a ionger infusion period changing trom2x500 mg to 2x1000 mg of ntumab                               |
| Protocol,D4 中8 Moy 2009                                                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Noutcaten ef me new doeage of me inisal teatment.                                                                                    |
| ProtocolvD6                                                                              | Added that pregnancy test should be perloed belore any aaministaSon ef reuimab                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | To update that pregnancy test should not be only at he start of he pretocol                                                          |
| 20 January 2010                                                                          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                                                                                                      |

<div style=\"page-break-after: always\"></div>

## Summary of Select Key Changes to the Protocol (cont.)

| Document Verion, Dat        | Summary of Key Change                                                                                                                                                                                                                                                                                                                                                                                    | Rationale for Change                                                                                                                                                                                             |
|-----------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Protocot,v.07 13 ty 2010    | lnclugion crenon amended lo read patent nanng recemed le than one monh of eystemiccorticoeteroid herapy at a dose sO.5 mggkd or local corticosheroid terapy pnor to the eMeaie bing dagnotesr                                                                                                                                                                                                            | Cates of pmphigue treated pnior to te dugnotie by non-ipeclecoticosterod erapy (Ho 5mp/g/ay) proven ineffectve against pemphigus were not intenbionaly eutludtd, becaute De pracbce ofa undsgnotid oral eoeiong. |
| Protocolv09 16 June 2011    | Patent intormation eheets amended to includefour comH of tatal lupea pue uotnu bn ue o buunp buwnoo tuogetu deach have been reoorted in patenes treated for rheumatoig arrca Two cf hete patents had underying nean dseate Tneve fatal reacticns are rare.oien he number cf pretonpbono lor Rucuuimab since its marietng                                                                                 | Satety nfomation provided by Te Apolicant                                                                                                                                                                        |
| Pretoco,v11 03 January 2013 | Updaied pattnt afety lnfomaton:The deecnpton cf enceptonal cases overe sln reactons (odc eodemal necrehyis meNl o Svene-Jonnnon tyndrome (SJSi aherawariable peniod from Mveral houn up to 4 mons aher e fest infution, must lead to the patient being ciosely monnoned investgaton must inform patents that my must immedately problems wih balance or movement coordinatien,er eaperlence any conueicn | Salety intormiation proiotd by tne Applcant                                                                                                                                                                      |

## Summary of Select Key Changes to the Protocol (cont.)

| Document Veron,Date      | Summary of Key Change                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | Ratonale for Change                                                      |
|--------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------|
|                          | Long-em pharmacoviglance data In Ight ef me deseripton cf enceotonal cates of lymphoma or PML (n lupuo patents onyl. of severe slin reactons in patents with auto-immune diseases. folow-up of the patents in tne tral will be conducted by telephone upto 10 years aher breatment in order to ensure hat there are no ong-em eide enects.ln ne laner case, vere eiun .reoctoos callea Lyelfesyndrome and Stevent-Johnson symdrome caue ipotmal neeroes,a detachmunt of ne tun, Hmlar in tome cates.Tne mechanigm of mese reactons is unknown, but immed ate disconbnuation of study mec cabon                                      | Salety lntormation provided by the Appicant                              |
| Protocolv12 31 March2014 | in aodton,tome cose of vial hepas,some of which are Hevere or fatal, nave occumed in pabents treated with rtuimab for motl probably lnied to a rtattvation ef ne hepatte B virus by nhuximab n combnshon wm cnemothapy (in catents wim hymphoma) and/er corteone (in paents win polyartrti) Nene o! bndudhubd Jo:pacen cutcedupeguoeeouoog beytoieobeun Wih Rluomab in eir lves that was lnked so he hepatts B virus, to have hear blood scneened,and i there are signs of reactvaton of hs complance utn current reconumendation scheduled to ensure pood long-tem tolerance to treatment which you have recelved during his tudy. | Safety intomaton provded by the Appicant and request for study ertension |

<div style=\"page-break-after: always\"></div>

Summary of Select Key Changes to the ProtocoT(cont)

| Document Veron,Date      | Summary ofKey Change                                                                                                                                                                                                                                                                                                                            | Ratonale for Change                                                              |
|--------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------|
|                          | Adoed Secondary Endpcints Tne number ofpatentsin complene remistion,who contnue minimal coreoered erapy （Frednne-10mg/eayi at M36 (4 mons）,cr are receing cotcoterod erapy foiowing one or more reiapees. The number  paentsin compete remson of reament at M36 (4mons) Cinicai folow-up extended to 36 monne                                   | Safety informabon provided by the Apocant and Sponeor reguen for study eatengion |
| Protocolv.13 25 Jum 2015 | Tne pnmary endpointwas chanoed from Evaluate me number of pa5ents in complete remistion during the M24 evaluation who have not recelved pyetemic cortcosterod therapy tor at leastmree montne'to'EvaluatePe numberelpalentsincompleleremition during the M24 evalua5on who have not receved syttemic corteosleroid ntapy tor at leat tee months | Upcate to Cinical Guidelnes(Murmell etal 2ooe)                                   |

AFFSAPSAgence Frangaie de Secune Santare des Produt de Sant

Protocol v was a working copy.Prctocol 2 was e venicn hat receiveda favorable recommendaton om he Commimee for the Protecton Perong 18 December 2oos.Protocol v5,8.and vt0 nad administratve changteonly.Protocol 14 lthe fnal verion.

## Major Protocol deviations

Major protocol deviations were defined by the sponsor as mistakes or technical deviations which could lead to danger for patients and could affect the integrity of the results of the study. In the ITT population, 197 major protocol deviations were reported in 77 patients (86%). Sponsor definitions were not reclassified or adjudicated by the Applicant, although upon review, many of the deviations categorized by the Sponsor as 'major' did not meet the Applicant's standard definition for a major protocol deviation. The Applicant's definition of a major protocol deviation is one that has the potential to impact patient safety, the efficacy of the treatment regimen, or the study analysis. Applicant review of the Sponsor's 'major protocol deviations' concluded that these deviations as collected and classified by the Sponsor did not have an impact on the overall interpretation of efficacy and safety results. No protocol deviations led to withdrawal of patients from the study. Per-protocol analysis was not performed for this study.

The major deviations observed in the ITT population were primarily procedural (e.g., ICF updates/versions not signed at the correct time [however, original ICFs were signed], information updates not signed, not dated, or lost) or medication-related (e.g., prednisone dose increases/decreases not per protocol guidance at some study visits). In the ITT-PV population, the deviations were balanced across the arms with 159 major protocol deviations being reported in 63 patients; 75 deviations in 32 patients in the rituximab + prednisone arm and 84 deviations in 31 patients in the prednisone arm.

The major deviations observed in the ITT PV population were similar to those seen in the ITT population.

To further investigate the potential significance of these protocol deviations, the Applicant undertook site visits at 8 of 25 centers, including the center with the most major protocol deviations. Review of the site visit findings indicate that the study centers addressed the issues identified during the site visits and confirmed that the findings observed did not have an impact on data integrity.

<div style=\"page-break-after: always\"></div>

## Table 5

Roche

Table Dsoo5IT:Major Protocol Deviations by Treatment Analysis Set:Intent to Treat PV

|                                                                    | Rituximab + Prednisone (N = 38) n (8)   | Prednisone (N = 36) n (8)   |
|--------------------------------------------------------------------|-----------------------------------------|-----------------------------|
| deviation on inclusion criterion                                   | 0 0.08)                                 | 2.88)                       |
| deviationonpharmacovigilance                                       | 2 5.38)                                 | 11.1$)                      |
| information letter/consent not found                               | 2 5.38)                                 | 1 2.88)                     |
| information letter/consent not signed                              | 14 36.88)                               | 1 2.88)                     |
| information letter/consentt to enrollment not appropriate          | 12 31.68)                               | 11 30.68)                   |
| informationletter/consent to enrollment not signed by investigator | 0 0.08)                                 | 1 2.88)                     |
| information letter/consent to enrollment signature not appropriate | 0 0.08)                                 | 1 2.88)                     |
| pharmacy technical deviation                                       | 1 2.68)                                 | 0 0.0%)                     |
| technical deviation on record at site                              | 3 7.98)                                 | 3 8.38)                     |
| trial treatment not followed                                       | 17 44.78)                               | 26 (72.28)                  |

## Baseline data

## Table 6

## Demographic Data(ITT-PV Population)

<!-- image -->

|                | Patinab.frednieone                            |                        | (2270)                 |
|----------------|-----------------------------------------------|------------------------|------------------------|
| Median M       | 21.                                           | 24 41.0 .0.03.5        | . 14.14 .07.0          |
| A Cr           |                                               |                        | 74                     |
| l Teale        | 中 29.9 71.11                                  | H.34                   | 13.26 5.11             |
| Pamlira Beiph  |                                               |                        |                        |
| edis ediAA     | 163.0 ONTPT 1.0. 31.0 124. .2 10.0..0 41. 199 | 190. 162.1. 74.1 ..0 1 | lee.8 961 171.0 85.20  |
| Bmlg（          |                                               |                        |                        |
|                | 21 0 中                                        | .7 8                   | 80.0.00.0 41, 197 86.0 |
| Barlin BC （g/） |                                               |                        |                        |
| Medin          |                                               | 17, 44                 | 22.0 27                |
| Medias MLE.    | 1 1-4                                         |                        | 1.6.1.9                |

中

Modifiedfromtdm001

<div style=\"page-break-after: always\"></div>

Table 7 Baseline Disease Characteristics(ITT-PV Population）

<!-- image -->

|                                     | GP357      | CD         |              |
|-------------------------------------|------------|------------|--------------|
| Fephpuo Walpuran                    | (100.04)   |            | 4 (309.04)   |
| inloial Diee Tp [a] Fephipa alparan | (F7.44)    | (150.04)   | 94.44)       |
| sc                                  |            |            | 19           |
| Sain Ony d Maesna Craloly (a Meam   | 0.0.204.0  | anoeho 12. | H.0          |
| rationeMaessal Leeiers Mean         | 1.9 1.     | 2M H       | H            |
| Fonterier PPEE Lirbe Te  y taot     | ciiin 5.31 | 1.31       | upuusse 0.84 |
| s e n Ooe ite TE2O P                | 口          |            | H H          |
|                                     |            | 20         |              |
|                                     |            | N.0.       |              |
| Dhar                                |            |            |              |
| Lel                                 |            |            |              |
| in Leisee n                         |            |            |              |
| FEAT                                |            |            |              |
| 14.55 60.8                          |            | 2.8 124    | 19..7.       |
|                                     |            |            | 72           |
|                                     | 0          |            | 13.0         |

erld . P

```
Feeoeeeapui ach baed oee. Pne and odsate defunedas Mogiflea trom tpeO0tt
```

Overall, 74 patients (82.2%) had a diagnosis of PV and 16 patients had a diagnosis of PF (Table 8). Baseline characteristics for the ITT population are presented in Table 8. Baseline disease history is presented in ldm003it which can be found in the submitted dataset

<div style=\"page-break-after: always\"></div>

Table 8 Baseline Disease Characteristics (ITT Population)

<!-- image -->

| TU                                |                                |             |                  |
|-----------------------------------|--------------------------------|-------------|------------------|
|                                   | 2.21)                          |             | SPS\"             |
| Hacon Cil Dral Only               |                                |             |                  |
| and Msetea Blin Only pl Oral only |                                |             |                  |
| Duraslee ef Mocstal Lenlens       | 7 0.0.824.0 02110 111.4 105.07 | OHT G7 H    | 12.0.111.0 61119 |
| Sedies                            |                                | 7           | 7                |
| P pig                             |                                | 45.4        | 44.71)           |
| Medlen                            |                                |             | 品                |
| FEA                               |                                | 品           |                  |
|                                   |                                | 7 24.1. 5.0 | 26.49            |
| Farmetaby Ieda                    |                                |             |                  |
|                                   | CRRC                           |             |                  |
|                                   | 47.41                          |             |                  |
|                                   |                                |             | 20.0,M.0         |
|                                   | 49.8                           |             |                  |
|                                   | 14.0                           |             |                  |
|                                   |                                |             | 111              |
| M                                 |                                |             |                  |

<div style=\"page-break-after: always\"></div>

## Numbers analysed

## Table 9

## Summary of AnalysisPopulations(ITT Population)

<!-- image -->

## Outcomes and estimation

Table 10 OvervlewofEfficacy in theITT-PVPopulation

<!-- image -->

|                                                                                    | Rituimab+ Prednisone N-38   | Prednisone N-36      |
|------------------------------------------------------------------------------------|-----------------------------|----------------------|
| Primary Endpoint CRoff prednsone 22months at M24                                   |                             |                      |
| Number of reeponden (n []] Dienence n reeponee rates (p-valve                      | 34 (89.5%)                  | 10 (27.8%) 0.0001    |
| CRoff prednisone 23months at M24                                                   |                             |                      |
| Number ol reoponden (n []) Dirference inretponve rates (p-value)                   | 34 (89.5%)                  | (25.0%) 00001        |
| Secondary Endpoints\"                                                               |                             |                      |
| Number otpatents who had at least one Severe/Voderate Relapse at M24 (n (s])       | 9 (23.7%)                   | 18 (50.0%)           |
| CR at M24 on Minimal Prednisone Treatment Number of pabents (n [%])                | 34 (89.5%)                  | 12 (33.3%)           |
| Total Cumulative Dose of Prednisone at M24 Mean cumulative dose (SD)(mg)           | 7356.4(5736.59)             | 21,845.3 (11,755.81) |
| Median cumulative dose (min, max) (mg)                                             | 5799.5 (2304,29303)         | 20520 (2409,60565)   |
| Duration of CRoff prednisone at M24in responders                                   |                             |                      |
| Number of responders                                                               | 34                          | 10                   |
| Medan duration of CRoff prednieone2monte at M24 (min,maxXdays) PROIQuality of Life | 498.5(91,609)               | 125.0 (56,680)       |
| Wean Siinden-France core ot M24 (mean [5D) change trom baseine)                    | 12.3 (-40.5)                | 21.5 (-37.5)         |
| Mean DLOl ecore at M24 (mean |5D] change from (euesea                              | 1.7(-7.9)                   | 3.6 (-7.4)           |

CR=complete nemision;CRoff-complete remision off prednisone therapy DLOl Dematology Qualty of Lile Inde;TTintent-to-treat M month; PROpatient reporied outcomes

p-value is from Fisher'sexact test with mid-p correction

No adjustment formultiplicity was made for secondary endpointe.

Onginal prmary endpoint was CRoff prednisone23months at M24 colected on e case report forme and updated to CRoff pnednisone 22monthe at M24 to refleci publiahed clinical ouldelnes (Munel et al.2000)

<div style=\"page-break-after: always\"></div>

## Primary endpoint (CR off prednisone therapy for 2 months or more at month 24)

At  M24,  the  proportion  of  PV  patients  with  CRoff  prednisone  for  2  months  or  more  was  statistically significantly higher in the rituximab + prednisone arm than in the prednisone arm (34 patients [89.5%] vs. 10 patients [27.8%], p-value &lt;0.0001). The unadjusted risk ratio comparing the rituximab + prednisone arm to the prednisone arm was 3.2 (95% CI 1.9, 5.5; p-value &lt;0.0001). Similar risk ratios were obtained when adjusted for gender and baseline PDAI scores in a log-binomial model (3.2 [95% CI 1.9, 5.6; p-value 0.0001] and 3.0 [95% CI 1.7, 5.2; p-value 0.0001], respectively).

Results from logistic regression models are presented. The unadjusted odds ratio was 22.1 (95% CI 6.2, 78.5; p-value &lt;0.0001). After adjusting for gender, the odds ratio was 23.0 (95% CI 6.1, 87.3; p-value 0.0001) and after adjusting for baseline PDAI score, the odds ratio was 19.6 (95% CI 5.4, 70.5; p-value &lt;0.0001).Gender breakdown of the primary endpoint by treatment arm was as follows: 90.9% and 28.6% for  males;  and  88.9%  and  26.7%  for  females  between  rituximab  +  prednisone  and  prednisone  arms, respectively.

## Secondary outcomes

An overview of the results on secondary outcomes is provided in table 11. All between-group differences in secondary outcomes were in favour of the rituximab treated group.

<div style=\"page-break-after: always\"></div>

Table 11 Overview of Efficacy Endpoints inPatients with Pemphigus (ITT-PVPopulatlonStudyML22196)

|                                                                                                                     | Rituximab+ Prednisone N-J8   | Prednisone N-36     |
|---------------------------------------------------------------------------------------------------------------------|------------------------------|---------------------|
| Primary Endpoint CRoff 22monthsat M24                                                                               |                              |                     |
| Number of responders (n [%]) Difference in response rates (p-value*)                                                | 34 (89.5%) <0.0001           | 10 (27.8%)          |
| CRoff 2Jmonths at M24 Number of responders (n [%]) Secondary Endpoints\"                                             | 34 (89.5%)                   | 9 (25.0%)           |
| Severe and Moderate Relapses st M24 Number ofpabents who had at least one Severe/Moderale Relapse at M24 (n [D)     | 9(23.7%)                     | 18 (50.0%)          |
| CR at M24 on Minimal Prednisone Treatment Number of pabents (n [%]) Total Mean Cumulative Dose of Prednisone at M24 | 34 (89.5%)                   | 12(33.3%)           |
| Mean cumulative dose (SD) (mg)                                                                                      | 7356.4 (5736.59)             | 21845.3 (11,755.81) |
| Median cumulative dose (min,max)(mg)                                                                                | 5799.5 (2304,29303)          | 20520 (2409,60,565) |
| Duration of CRoff at M24 in responders                                                                              |                              |                     |
| Number of responders                                                                                                | 34                           | 10                  |
| Median duration of CRoff22months at M24in days (01,03)                                                              | 498.5 (91, 609)              | 125.0 (56,680)      |
| PROlOuality ofLife                                                                                                  |                              |                     |
| Mean Skindex-France score at M24 (mean[SD) change trom baseine)                                                     | 123(-40.5)                   | 21.5(-37.5)         |
| Mean DLQi score at M24 (mean[SD]change trom baseline)                                                               | 1.7 (-7.9)                   | 3.6(-7.4)           |

CR=complele remission CRF-case report form;CRoff  complete remission off prednisone therapy.DLOl=DermatologyOualty of Lle Index,ITT=inlenl-lo-treatM=month Max-macimum;Min-minimum,PRO-patient-reported outcome:Q1-lowerquartile: Q3-upper quarile:SD-standard deviation.

p-valueis trom Fishersexacl lest wth mid-p conecion

Original primary endpoint was CRoff≥3months at M24 and updated to CRoff ≥2monthsat M24 to relect published cinical guidelines(Murrelletal 2008).CRoff 23monthswas the

No adjustment formultiplicity was made for secondary endpoints

Souroe:ML22196 CSR Table 12

The duration of remission while off corticosteroids (in patients who were responders at month 24) was longer in the rituximab group as compared to the corticosteroid-only treated group.

At 24 months, the proportion of patients in clinical remission while receiving a minimal dose of prednisone ( ≤ 10 mg/day) in the rituximab group was identical to the proportion of patients off corticosteroids, but in the corticosteroid-only group there were 2 patients more as compared to the primary outcome (off corticosteroids).

In the rituximab treated group, the number of patients having had severe/moderate relapses up to month

<div style=\"page-break-after: always\"></div>

24 was smaller than in the corticosteroid-only group (Table 12). Also, the number of patients having had more than one relapse was larger in the corticosteroid-only treated group.

Table 12 Numberof RelapsesperPatlentat Month24(ITT-PV Population,StudyML22196)

|                                                   | Rituimab+ Prednisone (N-38)   | Prednisone (N=36)   |
|---------------------------------------------------|-------------------------------|---------------------|
| Severe/moderale relapses per patient by M24,n (%) |                               |                     |
|                                                   | 29(76.3%)                     | 18 (50.0%)          |
|                                                   | p-0.0163                      | p-0.0163            |
| 1                                                 | 7(18.4%)                      | 11(30.6%)           |
| 2                                                 | 2(5.3%)                       | 6(16.7%)            |
| C                                                 | 0(0.0%)                       | 1(2.8%)             |
|                                                   | 0(0.0%)                       | 0(0.0%)             |

ITT-intent to treat,M-month:PV-pemphigus vulgaris

Note.p-values were calculated trom Fisher'sexacl test with mid-p correction

Source.ML22196CSR Table18

The cumulative dose of prednisone used in the rituximab treated group was about 30% of the cumulative dose used in the corticosteroid-only group (Figure 13).

Table 13

<!-- image -->

Source:lex0o3se

In the period between month 24 and month 36, there were 11 patients with a relapse in the corticosteroid-only treated group. There were two patients in the rituximab group who had a relapse, one of them had been in remission (CRoff) at month 24 (Table 14).  There were 94% (32/34) of patients who maintained CRoff in the rituximab group and 60% (6/10) who maintained CRoff in the corticosteroid-only group.

<div style=\"page-break-after: always\"></div>

Summary ofNumberofPatients Who Achleved CRoff at Month24but Relapsed at Month36 (ITT-PVPopulation,Study

Table 14 ML22196)

|                                                  | Rituximab+Prednisone (N-38)   | Prednisone (N-36)   |
|--------------------------------------------------|-------------------------------|---------------------|
| Achieved primary outcome (CRofi at Month24)      | 34                            | 10                  |
| Severe/moderate relapse at Month 36              | 1(2.9%)                       | 4 (40.0%)           |
| Severe/moderate skin relapse at Month 36         | 1(29%)                        | 2 (20.0%)           |
| Severe/moderalemucosal relapse at Month 36       |                               | 0                   |
| Severe/moderate mucocutaneous relapseat Month 36 | 0                             | 2 (20.0%)           |

CRoff-complete response off prednisone therapy.ITT-intent-to-treatPV-pemphigus vulgaris

Notes:Includes relapse events reported dunng Month36 orpost-Month 36 visit,occuming up to Month 4o from randomization f there was more than one relapse for apatient. only theLast relapse was incuded inthistable

Incudespatients with no data afler Month 24who were confirmed to be relapse-free Percentages are based on n (number ofpabents achieving pnmary endpoint) Source:ML22196 CSR Table21.ML22196 CSR Table EF014IT

## Figure 2 Median Prednisone Dose (mg/day) Over Time by Trial Treatment

Figure EX006SE: Median Prednisone Dose (mg/day) Over Time by Trial Treatment: Analysis Set: Safety PV

<!-- image -->

Source: EX001SE

<div style=\"page-break-after: always\"></div>

Figure 3 Number of Patients Who Were off or Using Minimum Corticosteroid Dose (&lt;=10 mg/day) Over Time

Figure EF023IT: Number of Patients Who Were Off or Using Minimum Corticosteroid Dose (&lt;= 10mg/day) Over Time Analysis Set: Intent to Treat PV

Source Table: Ex001SE

<!-- image -->

## Secondary endpoint: QoL

- Completion rates for the Skindex questionnaire were &gt;70% in the rituximab + prednisone arm and &gt;55% in the prednisone arm. Completion rates for the DLQI questionnaire were &gt;85%in the rituximab + prednisone arm and &gt;70%in the prednisone arm.
- Patients in both arms reported an improvement in Skindex-France scores from baseline to M3 and this improvement was maintained until M24.
- Patients in both arms reported a clinically meaningful improvement in DLQI scores from baseline to M3 and this improvement was maintained until M24.

## Skindex-France

The total Skindex-France score is calculated on a scale of 0 to 100 where higher scores mean greater impairment of the patient's health-related QoL. Completion rates for the Skindex questionnaire were &gt;70% in the rituximab + prednisone arm and &gt;55% in the prednisone arm (Table 15).

<div style=\"page-break-after: always\"></div>

Table 15 Completion ratesforPRO questionnaires

<!-- image -->

|                | Skindex                  | Skindex         | DLOI                     | DLOI            |
|----------------|--------------------------|-----------------|--------------------------|-----------------|
|                | Rrundmab+Prednisone no38 | Prednisone n-36 | Rututmab+Prednioone n-38 | Prednisone no36 |
| Baseline(Doyl) | 32 (84%)                 | 28 (76%)        | 38 (100%)                | 33(92%)         |
| M3             | 33(87%)                  | 27 (75%)        | 36(95%)                  | 28 (78%)        |
| M6             | 32 (84%)                 | 26 (72%)        | 35(92%)                  | 28 (78%)        |
| M9             | 32 (84%)                 | 26 (72%)        | 35(92%)                  | 28 (78%)        |
| M12            | 33(87%)                  | 23 (64%)        | 34(69%)                  | 27 (75%)        |
| M18            | 28(74%)                  | 22 (61%)        | 35(92%)                  | 26(72%)         |
| M24            | 29(76%)                  | 21(58%)         | 36(95%)                  | 26(72%)         |

PROopobent-reported outcomes

Souroe:tqs001in.tqs002ht

Figure 3 Mean (95% Cl) Skindex-France Score by Visit (ITT-PV)

<!-- image -->

Cl=confidence level

Modified from fqs003it

The mean Skindex-France score at baseline (Day 1) was lower in the rituximab + prednisone arm than in the prednisone arm (52.9 vs. 61.3). The mean change from baseline (SD) at M3 was -28.6 (24.47) in the rituximab + prednisone arm and -28.3 (22.92) in the prednisone arm. At M24, the mean Skindex-France score was 12.3 in the rituximab + prednisone arm compared to 21.5 in the prednisone arm. Mean change from baseline (SD) at M24 was -40.5 (22.84) in the rituximab + prednisone arm and -37.5 (23.22) in the prednisone arm. Similar results were obtained when Skindex-France scores were analyzed by mixed model repeated measures (MMRM). At the M24 visit, estimated mean change from baseline (SD) was -39.6 (4.39) in the rituximab + prednisone arm and -35.6 (5.03) in the prednisone arm.

## Dermatology life quality index

A total DLQI score is calculated on a scale of 0 to 30 where higher scores mean greater impairment of the patient's health-related QoL. A change in DLQI scores is considered clinically meaningful when a patient's DLQI  score  changed  by  at  least  4  points  from  the  previous  score.  Completion  rates  for  the  DLQI questionnaire were &gt;85% in the rituximab + prednisone arm and &gt;70% in the prednisone arm (Table 22). Mean  score  improvements  were  clinically  meaningful  at  M3  for  both  arms  and  the  improvement  was maintained in both arms until M24 (Figure 4).

Monthi

<div style=\"page-break-after: always\"></div>

Figure 4 Mean (95% CI) DLQl Score by Visit (ITT-PV)

<!-- image -->

Cl=confidence interval; DLQl=Dematology Quality of Life Index

Source: fqs004it

Exploratory endpoint: Number of patients who relapsed at month 36

<!-- image -->

## Summary of main study

The  following  tables  summarise  the  efficacy  results  from  the  main  studies  supporting  the  present application. These summaries should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment (see later sections).

Table 1. Summary of Efficacy for trial ML22196

| Title: Comparison of treatment with anti-CD20 monoclonal antibody rituximab (Mabthera) in combination with short-term systemic corticosteroid therapy compared to long-term systemic corticosteroid therapy in patients with Pemphigus.   | Title: Comparison of treatment with anti-CD20 monoclonal antibody rituximab (Mabthera) in combination with short-term systemic corticosteroid therapy compared to long-term systemic corticosteroid therapy in patients with Pemphigus.                                                                                                                                                                                                                                                                                                                               | Title: Comparison of treatment with anti-CD20 monoclonal antibody rituximab (Mabthera) in combination with short-term systemic corticosteroid therapy compared to long-term systemic corticosteroid therapy in patients with Pemphigus.                                                                                                                                                                                                                                                                                                                               |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                                                                          | ML22196                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | ML22196                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Design                                                                                                                                                                                                                                    | This was a Phase III, randomized, active-controlled, open-label, multi-center, investigator-sponsored study. Patients with newly diagnosed pemphigus (vulgaris or foliaceus) were randomised 1:1 to receive rituximab in combination with short-term, low dose systemic corticosteroids (oral prednisone) or standard dose systemic corticosteroid therapy, for 24 months. Randomisation was stratified for disease severity. A follow-up visit was performed at month 36. Main analyses were performed in the majority subgroup of patients with pemphigus vulgaris. | This was a Phase III, randomized, active-controlled, open-label, multi-center, investigator-sponsored study. Patients with newly diagnosed pemphigus (vulgaris or foliaceus) were randomised 1:1 to receive rituximab in combination with short-term, low dose systemic corticosteroids (oral prednisone) or standard dose systemic corticosteroid therapy, for 24 months. Randomisation was stratified for disease severity. A follow-up visit was performed at month 36. Main analyses were performed in the majority subgroup of patients with pemphigus vulgaris. |
|                                                                                                                                                                                                                                           | Duration of main phase: Duration of Run-in phase: Duration of Extension phase:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 24 months Not applicable 12 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Hypothesis                                                                                                                                                                                                                                | Superiority                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Superiority                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |

<div style=\"page-break-after: always\"></div>

| Treatments groups                                                   | Rituximab and corticosteroids                                                                     | Rituximab and corticosteroids                                                                     | Rituximab and corticosteroids                                                                     | N=38. Rituximab 1000 mg iv was given at baseline and after 2 weeks, and as 500 mg iv at month 12 and month 18 as maintenance treatment. Corticosteroids were started at 1.0 mg/kg/day (severe disease) or 0.5 mg/kg/day (moderate disease) and tapered during 6 to 3 months, respectively.   | N=38. Rituximab 1000 mg iv was given at baseline and after 2 weeks, and as 500 mg iv at month 12 and month 18 as maintenance treatment. Corticosteroids were started at 1.0 mg/kg/day (severe disease) or 0.5 mg/kg/day (moderate disease) and tapered during 6 to 3 months, respectively.   |
|---------------------------------------------------------------------|---------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                     | Standard corticosteroids                                                                          | Standard corticosteroids                                                                          | Standard corticosteroids                                                                          | N=36. Corticosteroids were started at 1.5 mg/kg/day (severe disease) or 1.0 mg/kg/day (moderate disease) and tapered during 18 to 12 months, respectively.                                                                                                                                   | N=36. Corticosteroids were started at 1.5 mg/kg/day (severe disease) or 1.0 mg/kg/day (moderate disease) and tapered during 18 to 12 months, respectively.                                                                                                                                   |
| Endpoints and definitions                                           | Primary endpoint                                                                                  | CRoff 2 months at 24 months                                                                       | CRoff 2 months at 24 months                                                                       | Complete remission (complete epithelialization and absence of new and/or established lesions) at Month 24 without corticosteroid therapy for at least 2 months.                                                                                                                              | Complete remission (complete epithelialization and absence of new and/or established lesions) at Month 24 without corticosteroid therapy for at least 2 months.                                                                                                                              |
|                                                                     | Secondary endpoints                                                                               | Number of relapses                                                                                | Number of relapses                                                                                | Proportions of patients with >1 severe/ moderate relapse (specified criteria) from baseline to months 24.                                                                                                                                                                                    | Proportions of patients with >1 severe/ moderate relapse (specified criteria) from baseline to months 24.                                                                                                                                                                                    |
|                                                                     |                                                                                                   | CR minimal CS                                                                                     | CR minimal CS                                                                                     | Complete remission at Month 24 with minimal CS treatment (≤10 mg/day).                                                                                                                                                                                                                       | Complete remission at Month 24 with minimal CS treatment (≤10 mg/day).                                                                                                                                                                                                                       |
|                                                                     |                                                                                                   | Duration of remission                                                                             | Duration of remission                                                                             | The mean duration of complete remission (healing of the mucocutaneous lesions) without general corticosteroid therapy at                                                                                                                                                                     | The mean duration of complete remission (healing of the mucocutaneous lesions) without general corticosteroid therapy at                                                                                                                                                                     |
|                                                                     |                                                                                                   | Cumulative prednisone                                                                             | Cumulative prednisone                                                                             | Cumulative dose of prednisone from baseline up to month 24.                                                                                                                                                                                                                                  | Cumulative dose of prednisone from baseline up to month 24.                                                                                                                                                                                                                                  |
|                                                                     |                                                                                                   | CRoff at 36 months                                                                                | CRoff at 36 months                                                                                | Maintained complete remission of month 24 to month 36.                                                                                                                                                                                                                                       | Maintained complete remission of month 24 to month 36.                                                                                                                                                                                                                                       |
| Database lock                                                       | Last patient out: 22th March 2016 Data transfer from sponsor to applicant: December 2016          | Last patient out: 22th March 2016 Data transfer from sponsor to applicant: December 2016          | Last patient out: 22th March 2016 Data transfer from sponsor to applicant: December 2016          | Last patient out: 22th March 2016 Data transfer from sponsor to applicant: December 2016                                                                                                                                                                                                     | Last patient out: 22th March 2016 Data transfer from sponsor to applicant: December 2016                                                                                                                                                                                                     |
| Results and Analysis                                                | Results and Analysis                                                                              | Results and Analysis                                                                              | Results and Analysis                                                                              | Results and Analysis                                                                                                                                                                                                                                                                         | Results and Analysis                                                                                                                                                                                                                                                                         |
| Analysis description Analysis population and time point description | Primary Analysis ITT analysis in the Pemphigus Vulgaris subpopulation from baseline to 24 months. | Primary Analysis ITT analysis in the Pemphigus Vulgaris subpopulation from baseline to 24 months. | Primary Analysis ITT analysis in the Pemphigus Vulgaris subpopulation from baseline to 24 months. | Primary Analysis ITT analysis in the Pemphigus Vulgaris subpopulation from baseline to 24 months.                                                                                                                                                                                            | Primary Analysis ITT analysis in the Pemphigus Vulgaris subpopulation from baseline to 24 months.                                                                                                                                                                                            |
| Descriptive statistics and estimate variability                     | Treatment group                                                                                   | Treatment group                                                                                   | Rituximab + corticosteroids                                                                       | Rituximab + corticosteroids                                                                                                                                                                                                                                                                  | Corticosteroids-only                                                                                                                                                                                                                                                                         |
|                                                                     | Number of                                                                                         | Number of                                                                                         | n=38                                                                                              | n=38                                                                                                                                                                                                                                                                                         | n=36                                                                                                                                                                                                                                                                                         |
|                                                                     | CRoff 2 months                                                                                    | CRoff 2 months                                                                                    | 90% (34/38)                                                                                       | 90% (34/38)                                                                                                                                                                                                                                                                                  | 28% (10/36)                                                                                                                                                                                                                                                                                  |
|                                                                     | Variability statistic                                                                             | Variability statistic                                                                             | Not provided                                                                                      | Not provided                                                                                                                                                                                                                                                                                 | Not provided                                                                                                                                                                                                                                                                                 |
| Effect estimate per comparison                                      | Primary endpoint                                                                                  | Primary endpoint                                                                                  | Comparison groups                                                                                 | Comparison groups                                                                                                                                                                                                                                                                            | Rituximab versus corticosteroids-only                                                                                                                                                                                                                                                        |
|                                                                     |                                                                                                   |                                                                                                   | Fisher's Exact test                                                                               | Fisher's Exact test                                                                                                                                                                                                                                                                          | --                                                                                                                                                                                                                                                                                           |
|                                                                     |                                                                                                   |                                                                                                   | Variability statistic                                                                             | Variability statistic                                                                                                                                                                                                                                                                        | --                                                                                                                                                                                                                                                                                           |
|                                                                     |                                                                                                   |                                                                                                   | P-value                                                                                           | P-value                                                                                                                                                                                                                                                                                      | <0.0001                                                                                                                                                                                                                                                                                      |
| Notes                                                               | See flow chart (Figure 2) for size of total (PV + PF) population.                                 | See flow chart (Figure 2) for size of total (PV + PF) population.                                 | See flow chart (Figure 2) for size of total (PV + PF) population.                                 | See flow chart (Figure 2) for size of total (PV + PF) population.                                                                                                                                                                                                                            | See flow chart (Figure 2) for size of total (PV + PF) population.                                                                                                                                                                                                                            |
| Analysis description                                                | Secondary analysis                                                                                | Secondary analysis                                                                                | Secondary analysis                                                                                | Secondary analysis                                                                                                                                                                                                                                                                           | Secondary analysis                                                                                                                                                                                                                                                                           |
| Analysis population and time point description                      | ITT analysis in the Pemphigus Vulgaris subpopulation from baseline to 36 months.                  | ITT analysis in the Pemphigus Vulgaris subpopulation from baseline to 36 months.                  | ITT analysis in the Pemphigus Vulgaris subpopulation from baseline to 36 months.                  | ITT analysis in the Pemphigus Vulgaris subpopulation from baseline to 36 months.                                                                                                                                                                                                             | ITT analysis in the Pemphigus Vulgaris subpopulation from baseline to 36 months.                                                                                                                                                                                                             |
|                                                                     | Treatment group                                                                                   | Treatment group                                                                                   | Rituximab + corticosteroids                                                                       | Rituximab + corticosteroids                                                                                                                                                                                                                                                                  | Corticosteroids-only                                                                                                                                                                                                                                                                         |

<div style=\"page-break-after: always\"></div>

|                                | Number of subjects                | n=38                      | n=36                                  |
|--------------------------------|-----------------------------------|---------------------------|---------------------------------------|
|                                | Patients with relapses            | 24% (9/38)                | 50% (18/36)                           |
|                                | Variability                       | Not provided              | Not provided                          |
|                                | CR minimal CS                     | 90% (34/38)               | 33% (12/36)                           |
|                                | Variability                       | Not provided              | Not provided                          |
|                                | Median duration of remission*     | 490 days                  | 125 days                              |
|                                | (P25-P75)                         | (91-609)                  | (56-680)                              |
|                                | Median cumulative prednisone dose | 5800 mg                   | 20.520 mg                             |
|                                | (P25-P75) (Min-Max)               | (5030-7074) (2304-29.303) | (16.263-28.282) (2409-60.565)         |
|                                | CRoff maintained at 36 months     | 94% (32/34)               | 60% (6/10)                            |
|                                | Variability                       | Not provided              | Not provided                          |
| Effect estimate per comparison | Secondary endpoint                | Comparison groups         | Rituximab versus corticosteroids-only |
|                                | Patients with relapses            | Fisher's Exact test       |                                       |
|                                |                                   | Variability statistic     | --                                    |
|                                |                                   | P-value                   | 0.0163                                |
|                                | CR minimal CS                     | Fisher's Exact test       |                                       |
|                                |                                   | Variability statistic     | --                                    |
|                                |                                   | P-value                   | <0.0001                               |
|                                | Median duration of remission*     | Mann-Whitney U-test       |                                       |
|                                |                                   | Variability statistic     | --                                    |
|                                |                                   | P-value                   | 0.0030                                |
|                                | Median cumulative prednisone dose | Mann-Whitney U-test       |                                       |
|                                |                                   | Variability statistic     | --                                    |
|                                |                                   | P-value                   | <0.0001                               |
|                                | CRoff maintained at 36 months     | Test statistic            | Not provided                          |
|                                |                                   | Variability statistic     | --                                    |
|                                |                                   | P-value                   | --                                    |

<div style=\"page-break-after: always\"></div>

## 2.4.3. Discussion on clinical efficacy

## Design and conduct of clinical studies

The MAH has provided the results of the study MM22196, an open-label, phase III, multicentre, and randomised study in patients with newly diagnosed moderate to severe pemphigus. The study was run by academia (Rouen University Hospital, France). The MAH had no role in study design, conduct, data collection or publication of results. The database was transferred from the Sponsor to the MAH in December 2016 after database lock.

The open-label nature of the study may have led to bias, e.g. by overestimation of the beneficial effects of rituximab and/or overestimation of adverse events in the corticosteroid-only treated group. It is considered that also well designed and well conducted trials are prone to bias if open label, instead of double blinded. Especially, the primary outcome (clinical remission off corticosteroids for at least 2 months) is vulnerable for bias, since it relies completely on physician's judgement regarding the examination of lesions as well as the decisions regarding tapering. The primary outcome is thus not completely objective. The degree of experience/training of the investigators and standardisation of outcome assessment may contribute to reduction of bias due to the open-label design, although they cannot completely prevent it. Therefore, the CHMP requested sensitivity analyses, which are critical in assuring that a substantial part of the observed effects could not be explained by bias, and that accounting for the size of probable bias will not reduce the size of the treatment effects beyond clinical meaningfulness.

The main objective of the study was to investigate the possibility to control disease with rituximab in combination  with  low-dose  and  short-term  use  of  CS.  One  primary  endpoint,  several  secondary  and exploratory endpoints are defined. The primary endpoint is fully acceptable from a clinical point of view. The secondary  endpoints  are  clinically  meaningful  and  relevant  endpoints  that  all  supplement  the  primary endpoint.

## Primary endpoint

The primary outcome as originally proposed by the sponsor-investigator, CRoff for 3 months, was changed post-hoc by the Applicant to CRoff for 2 months, in reference to the outcome guideline [Harman 2008]. The original outcome (CRoff for 3 months) is also presented, which is understood as sensitivity analysis rather than as secondary outcome or co-primary outcome; correction for multiplicity is therefore unnecessary.

According to the protocol and CRF, photographs were taken at all time points. However, according to the Applicant, photographs were not taken systematically and standardized methods for photographic assessment were not implemented in this study. Unfortunately, blinded assessment of photographs is no option to at least partly circumvent the unblinded nature of the study.

Patient global assessment (PGA), Pemphigus Disease Area Index (PDAI) and the Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) questionnaires were included in the CRF just before the questions on clinical status, apparently for a validation study. PDAI and ABSIS are regarded as established instruments for pemphigus [Harman 2017]. The Applicant was asked to discuss the validity and reliability of including PGA, PDAI and ABSIS as outcomes and include them in the results if justifiable. It is understood that results on PDAI and ABSIS will be separately reported, as validation study but not in the context of the current study. This is accepted; PDAI and ABSIS will not necessarily add to the interpretation of the treatment effects.

The primary and secondary outcomes concentrate on month 24 and month 36. However, it is considered clinically  relevant  to  also  assess  the  disease  course  between  baseline  and  month  24.  Therefore,  the Applicant was asked to perform between-group analyses of appropriate outcomes, for example: proportion of patients 'in control' (start of tapering), time-to-clinical remission, time-to-first-relapse, proportions of patients in CRoff for all time points, patients in CR for all time points, patients with minimal corticosteroids

<div style=\"page-break-after: always\"></div>

at all time points, PGA, PDAI and ABSIS over time. The outcomes (1-7) of intermediate time points between baseline and month 24 support the efficacy of rituximab+prednisone versus high dose prednisone. Some of the results, e.g. time to CRoff for 2 months and prednisone use ≤10 mg/day might be considered for the EPAR. Also for that purpose, survival curves would have been preferred over analysis of medians for the 'time-to-event' data. Despite baseline differences in PDAI of median (P25-P75) 55 (27-63) in the prednisone arm versus 26 (14-41) in the rituximab+prednisone arm, in both arms PDAI reduced to a median of 0 in 6 months.

Baseline demographics showed an imbalance with regard to gender, but this is not expected to have any major impact on the interpretation of results. Overall, the baseline disease characteristics are well-balanced.

## Maintenance treatment /choice of dose

The studied initial dose of rituximab 2x1000 mg iv 2 weeks apart was chosen because of its known B-cell depleting effects, which is acceptable as rationale for choice in this confirmatory 'phase 3' trial. B-cell depleting effects were also seen in a small (n=21) cohort of patients with pemphigus treated with rituximab in a regimen as for ANCA-positive Vasculitis, which is supportive. Premedication was given before infusion with rituximab, in agreement with the SmPC for rheumatoid arthritis.

The studied maintenance dose of rituximab was 500 mg iv at months 12 and 18, which had been applied in ANCA-positive vasculitis. The rationale was to prevent the common relapses in pemphigus, which is accepted as rationale for its choice in the phase 3 study.

The maintenance treatment wording as proposed in the SmPC was discussed with the applicant during the assessment and agreed as follows :

## 'A maintenance infusion of 500 mg IV should be administered at months 12 and 18, and then every 6 months thereafter if needed,  based on clinical evaluation.'

## Treatment of relapses

For pemphigus vulgaris, retreatment to prevent relapses or to treat residual disease activity other than flares is currently unjustified.

For treatment of relapses it is proposed in the SmPC to administer rituximab 1 x 1000 mg, not sooner than 16 weeks after a previous infusion with rituximab. Corticosteroid treatment may be resumed. This is similar as performed in the study and could therefore be agreed. The period of 16 weeks comes from the experience in RA, which is accepted. According to the MAH, findings in RA patients demonstrated peripheral B-cell recovery between 6 to 9 months after treatment, and as early as 16 weeks. It can be assumed that the B-cell depleting effects of rituximab are similar for RA patients and PV patients.

It is agreed that corticosteroid is used concomitant to rituximab, to 'bridge' the period that rituximab will begin to become effective. This is in line with treatment guidelines for pemphigus for start of immune suppressive treatment [Harman 2017]. There are no firm guidelines for starting dose, tapering and treatment of flares using corticosteroids in pemphigus, but the implemented corticosteroid schemes are in line with treatment guidelines [Murrell 2008; Harman 2017]. This includes that it is waited for 3-4 weeks or longer till disease activity is 'in control' before tapering is started, as was performed in the study.

The criteria for disease activity being 'in control' and for 'flares' were in agreement with established consensus definitions [Murrell 2008].

## Efficacy data and additional analyses

The  study  met  its  primary  endpoint  showing  a  statistically  significant  and  clinically  relevant  difference between  the  treatment  arms  in  favour  of  rituximab.  In  total  89.5%  (34/38)  of  the  patients  in  the

<div style=\"page-break-after: always\"></div>

rituximab+prednisone arm had CR off prednisone therapy for at least 2 months at month 24. In comparison only 27.8% (10/36) of the patients in the prednisone arm experienced CR off prednisone for at least 2 months at month 24. Looking at CRoff prednisone for at least 3 months at month 24 (the original primary endpoint) similar results are observed. No single centre was dominating the inclusion, which is supportive for robustness of the results.

Differences in baseline variables between treatment groups were overall relatively small, except for gender and PDAI for which sensitivity analyses for the primary outcome were performed. Importantly, disease severity and pattern of lesions were similar at baseline.

In the primary outcome, clinical remission off corticosteroids for at least 2 months (at month 24), there was a numerically large and statistically highly significant (p&lt;0.0001) treatment effect between the rituximab group (90%) and the corticosteroid-only group (28%). The size of this treatment effect would be regarded as clinically relevant. The results are supported by the results of the sensitivity analyses (CRoff for 3 months, CRoff in total PF+PV sample, correction for gender and for baseline PDAI). There was no evidence for confounding, or effect modification, by gender.

According to the sensitivity analyses: a) if patients in the prednisone arm who withdrew from treatment or did not complete the month 24 visit were assumed to be responders, the effect in CRoff for rituximab+prednisone versus high dose prednisone was: 90% versus 62%, and it can be calculated that the 95%-CI for the difference is above 6.8%; b) if patients in the prednisone arm who withdrew from treatment or did not complete the month 24 visit were removed from analysis, the effect in CRoff was 90% versus 42%; c) a conservative CRoff in the rituximab+prednisone arm just lower that the lower limit of the 95%CI for the rituximab+prednisone arm of 74% supported the robustness of the treatment effects in the sense that the difference would still at least be 20% (according to the 95%-CI for the difference). This argument can be taken a few steps further: if the rituximab+prednisone arm would have a response rate of 68.4% (26/38), 63.2% (24/38), 57.9% (22/38), 52.6% (20/38) then the difference would still at least be 15%, 10%, 5%, 0% respectively.

The explanation of the MAH that the probable bias due to the open-label design on the cumulative corticosteroid exposure would have been in favour of the high-dose corticosteroids (ie. in fact turned out to be conservative) is not followed. If patients on rituximab+prednisone who relapsed and still achieved CRoff at month 24 were treated as non-responders, the effect in CRoff would be 76% for rituximab+prednisone versus 30% for high dose prednisone. Overestimation of relapse in the high dose prednisone group was not considered by the applicant.

In summary, it cannot be excluded that bias occurred in favour of rituximab+prednisone through the open-label design of the study. However, the treatment effect was large and the sensitivity analyses show that it is unlikely that the 'real' treatment effect is clinically insignificant.The results of all secondary outcomes were supportive for the results of the primary outcome. For the between-group differences regarding corticosteroid-related adverse events it is referred to the safety section.

The duration of remission while off corticosteroids (in patients who were responders at month 24) was longer in the rituximab group as compared to the corticosteroid-only treated group. The MAH confirmed that duration of remission was cumulative.

Prednisone dose is more appropriately presented as median (P25-P75) instead of using mean. The Applicant was asked to adapt the graphical presentation (Figure 9) for median corticosteroid dose and to supply a graph with proportions of patients off corticosteroids or using a minimal dose (≤10 mg/day) of corticosteroids. The graphical presentations of median prednisone dose over time and of no-or-minimal (≤10 mg/day) prednisone dose are considered to be supportive for the claimed steroid sparing effect of rituximab. This is now reflected in the SmPC.

<div style=\"page-break-after: always\"></div>

The study has been performed in patients with newly diagnosed pemphigus vulgaris, however considering the unmet medical need, the strong biological rationale, and the consistency of the published evidence on PD, efficacy and safety of rituximab in established PV, it is accepted that the indication include patients with established PV. There are nevertheless uncertainties due to the limitations of the data provided in the established disease. The CHMP considered that additional data are necessary to confirm the benefit of Mabthera in the subgroup of patients with established disease. The ongoing study in the relapsed setting, study WA29330 (PEMPHIX) will provide additional key information on the benefits and risks of Mabthera in these patients. The recruitment is completed and the preliminary and final analyses of this study should be provided post-approval. The results of ongoing study WA29330 in established PV will lead to SmPC changes, particularly in section 5.1.

The restriction of the main analyses to patients with pemphigus vulgaris is endorsed, based on the difference in numbers and differences in pathogenesis and prognosis with pemphigus foliaceus. Extrapolation to patients with pemphigus foliaceus is not attempted.

## 2.4.4. Conclusions on the clinical efficacy

Overall,  the  study  met  its  primary  endpoint,  showing  a  statistically  significant  and  clinically  relevant difference in favour of the rituximab arm. All secondary endpoints support the findings in primary endpoint.

The use of rituximab in combination with prednisone was studied in patients newly diagnosed with pemphigus vulgaris, but the claimed indication includes patients with established pemphigus vulgaris (relapsed setting). The MAH has justified the extrapolation, which includes a PK, PD, efficacy and safety discussion, by reasoning as well as by the already provided supporting evidence. This is acceptable to the CHMP. There are nevertheless uncertainties due to the limitations of the data provided in the established disease. The ongoing study will provide further information key to the benefit risk of Mabthera in the subgroup of patients with established disease.

## 2.5. Clinical safety

## Introduction

## Introduction

MabThera (rituximab) has been registered since 1998, for the treatment of Non-Hodgkin lymphoma and Chronic Lymphocytic Leukaemia (CLL). Since 2006, MabThera has also been registered for the treatment of severe rheumatoid arthritis, in patients who  cannot be treated with other DMARDs  including TNFalpa-inhibitors.  In  2013,  MabThera  was  approved  for  the  treatment  of  other  AI  (auto-immune) disorders, i.e. Granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA). GPA/MPA is also called ANCA-vasculitis.

Case report forms in this study were designed to collect non-serious treatment-related AEs and related and unrelated SAEs. Non-serious treatment-related AEs are those that were recorded on the AE page of the CRF and exclude IRR symptoms which were reported on a separate CRF page. Treatment-related AEs refer to both treatment-related AEs and treatment-related SAEs.

Safety data is analyzed and presented for the Safety PV population and DAP specified analyses were also performed on the full Safety population.

<div style=\"page-break-after: always\"></div>

Table 17

Treatment-Related Adverse Events,Including IRRs,All Serious Adverse Events,and Deaths Through Month24(Safety PV Population)

| heten Cegen Cam       | Rutuminb FoedLae   |        | Al1 Fatientn   |
|-----------------------|--------------------|--------|----------------|
| Potiente vath eente   | (9.25)             |        | (83.0%)        |
| Pte                   | (2.4)              |        |                |
| h                     | 7 Gt.41)           | 1.24   | （20.4)         |
| patleste vsth eente 电 | (2.)               | (22.21 | (22.24)        |
| l C D                 |                    |        |                |

-ey ae. 24

Modiled trom tse01Bee

## Patient exposure

Table 18

Extent of Exposure to Rituximab(SafetyPV Population)

To Ci Do Riinba oth  ng

Table 19

<!-- image -->

## Extent of Exposure toPrednisone (Safety PV Population）

|                       | Pitpinh   |   Fuedrieone |                |
|-----------------------|-----------|--------------|----------------|
| ene Dem at Baselingda | 1H        |         1049 | 福 0.0. 1461.0- |

ar e. E

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table 20

```
Analysis Bet: Safety FV
```

```
Rituximab + Prednisone (N = 38) Total Cumulative Dose of Rituximab at Day l （mg） n 37 Mean 1000.0 30 0.00 Medi an 1000.0 Q1,Q3 1000.0,1000.0 Min, Max 1000,1000 Total Cumulative Dose of Rituximab at Day 14 (mg) n 38 Mean 2013.2 3D 81.11 Medi an 2000.0 01.03 2000.0,2000.0 Min, Max 2000,2500 Total Cumulative Dose of Rituximab at Month 12 （mg) n 38 Mean 2578.9 3D 218.30 Medli an 2500.0 Q1,Q3 2500.0,2500.0 Min, Max 2000,3000 Oral prednisone is given as standard therapy for the Prednisone arm (starting at l mg/kg/day and tapered for over 12 months for moderate pemphigus or 1.5 mg/kg/day and tapered over 18 months for severe pemphigus)and as rediuced therapy for the Rituximab + Prednisone arm (starting at 0.5 mg/kg/day and tapered over 3 months for moderate pemphigus or 1 mg/kg/day and tapered over 6 months for severe pemphigus). Dose adjustments for relapse were also defined as per the protocol. n = number of patients with a non-missing value. Source data: Listing EX0023E Program:/data/prodl/elient01/ist-joly/final/programs/statout/texl02se.sas (FINAL) Date and Time: 02AUG2018 18:43:04 (Page 1 of 2) Analysis Set:Safety FV Rituximab + Prednisone (N = 36) Total Cumulative Dose of Rituximab at Month 18 （mg) n 38 3039.5 3D 269.67 Medi an 3000.0 Q1.03 3000.0,3000.0 Min, Max 2000,3500
```

<!-- image -->

```
Oral predinisone is given as standard therapy for the Predinisone arm (starting at 1 mg/kg/day and tapered for over 12 months for moderate pemphigus or 1.5 mg/kg/day and tapered over 18 months for severe pemphigus) and as reduced therapy for the Rituximab + Prednisone arm (starting at 0.5 mg/kg/day andl tapered over 3 months for moderate pemphigus or 1 mg/kg/day and n=number of patients with a non-missing value. Source data: Listing Ex002SE Program:/data/prodl/elient01/ist-joly/final/programs/statout/texl02se.sas (FINAL) Date andl Time: 02AUG2018 18:43:04
```

```
(Page 2 of 2)
```

<div style=\"page-break-after: always\"></div>

## Adverse events

## Common treatment-related Adverse Events

## Table 21

## Treatment-Related Adverse Events,Including IRRs,Oecurring in21o% of PV Patients by System Organ Class (Safety PV Population)

| lyeten Oogan Carny   | Ratuna o Freiee   | Foedlte   | All Fotieete   |
|----------------------|-------------------|-----------|----------------|
|                      |                   | （0.)      | （.)            |
| .m                   | 0.0               | 0.6       | 11.11          |
| Latald disoedens     | 1                 | .         | [4.M)          |
|                      |                   | (.)       | (11.21)        |
|                      |                   | 42.4      | 121.1)         |
| giensng em peelnl    | （                 | 1         | 1810           |
|                      | 2.                | .         |                |
|                      | FEE               | （.        |                |
|                      | 21.               | 120.41    | 111.M)         |
| Tal Se.en            |                   | 1(11.     |                |
| Toel Me.             | （19.54)           |           | 14111.         |
| Iyesen Cepan Case    |                   |           | Al leniense    |
|                      | 10.041            | .         | .              |
|                      | 021.00]           | (1.1)     | 14.20)         |
|                      | 12.04             | 业 121.1)  |                |

.

oep

Events coded as the Sytem Organ CiauwPvetered Term ofGeneral gitorden and administation pbe condtons/Musce disorder should begrouped wth events coded as Musculonieietal and connective Donue disorden/Muscie dsorder when interpreting n

Vodllea trom toe01fse

Anteritls indicate the population in which the AE occumed at a higher fhequency G5% dlflerence in frequency behween treatment arme)

<div style=\"page-break-after: always\"></div>

Table 22

Anterisks indicate he population in which the AE occurred at a higher thequency G5% dlenence In frequency between treatment arma).

<!-- image -->

## Treatment-related adverse events by intensity

Treatment-related AEs were categorized by intensity using CTCAE v4: mild (Grade 1), moderate (Grade 2), severe  (Grade  3),  and  life-threatening  (Grade  4).  In  the  rituximab  +  prednisone  arm,  28  Grade  3 treatment-related AEs were seen in 11 patients; in the prednisone arm, 53 Grade 3 treatment-related AEs were seen in 19 patients. The most frequent Grade 3 treatment-related AEs by PT (&gt;= 5%

in either treatment arm [rituximab + prednisone vs. prednisone]) were Cushing's syndrome (15.8% vs. 16.7%), muscle disorder (2.6% vs. 22.2%), myopathy (0% vs. 11.1%), fungal infection (5.3% vs. 5.6%), intervertebral disc compression (5.3% vs. 5.6%), major depression (5.3% vs. 2.8%), skin disorder (5.3% vs. 0%),), cataract (0% vs. 5.6%), lung disorder (0% vs. 5.6%), and weight increased (0% vs. 5.6%). In the rituximab + prednisone arm, 7 Grade 4 treatment-related AEs were seen in 2 patients (5.3%) and the PTs  were:  infective  thrombosis,  intervertebral  discitis,  sepsis,  staphylococcal  sepsis,  lung  disorder, pulmonary embolism, and femoral neck fracture. In the prednisone arm, 4 Grade 4 treatment-related AEs

<div style=\"page-break-after: always\"></div>

were seen in 3 patients (8.3%) and the PTs were: Cushing's syndrome (2.8%), weight increased (5.6%), and cardiac failure (2.8%).

There were no Grade 5 events in either treatment arm.

## Table 23

Grade3 AdverseEvents with Incidence atLeast 5 Analysis Set:Safety PV

| System Organ Class/ Preferred Term                   | Rituximab + Prednisone (N=38)   | Prednisone (N=36)   | All Patients (N=74)   |
|------------------------------------------------------|---------------------------------|---------------------|-----------------------|
| Any System Organ Classes                             |                                 |                     |                       |
| Total No.of patients with one or more events         | 12 (31.6%)                      | 24(66.78)           | 36(48.68)             |
| Total No.of events                                   | 33                              | 59                  | 92                    |
| Endocrine disorders                                  |                                 |                     |                       |
| Cushing's syndrome                                   | 6 15.88)                        | 7 （ 19.48)          | 13 3(17.68)           |
| Total No. of events                                  |                                 | 8                   | 17                    |
| Musculoskeletal and connective tissue disorders      |                                 |                     |                       |
| Intervertebral disc compression                      | 2 5.38)                         | 2 5.68)             | 5.48)                 |
| Myopathy                                             | 0 0.08)                         | 4 11.18)            | 4 5.48)               |
| Muscle disorder                                      | 2.68)                           | 2 5.68)             | 3 4.18)               |
| Myalgia                                              | 2 5.38)                         | 0 0.0%)             | 2 2.78)               |
| Total No. of events                                  |                                 | 13                  | 20                    |
| General disorders and administration site conditions |                                 |                     |                       |
| Muscle disorder                                      | 0 0.0%)                         | 6 16.7%)            | 8.18)                 |
| Total No.of events                                   |                                 | 7                   | 8                     |
| Infections and infestations                          |                                 |                     |                       |
| Fungal infection                                     | 5.38)                           | 2 5.68)             | 4 5.48)               |
| Total No. of events                                  |                                 | 4                   | 8                     |
| Respiratory, thoracic and mediastinal disorders      |                                 |                     |                       |
| Pulmonary embolism                                   | 2.68)                           | 2 5.68)             | 4.18)                 |
| Lung disorder                                        | 0 0.0%)                         | 2 5.68)             | 2 2.78)               |
| Total No.of events                                   | 1                               | 4                   | 5                     |
| Eye disorders                                        |                                 |                     |                       |
| Cataract                                             | 0 0.08)                         | 2( 5.68)            | 2 2.78)               |
| Total No.of events                                   | 0                               | 3                   | 3                     |
| Investigations                                       |                                 |                     |                       |
| Weight increased                                     | 0 0.08)                         | 3( 8.38)            | 3 （ 4.18)             |
| Total No.of events                                   | 0                               | 3                   | 3                     |
| Psychiatric disorders                                |                                 |                     |                       |
| Major depression                                     | 5.38)                           | 1( 2.88)            | 4.18)                 |
| Skin and subcutaneous tissue disorders               |                                 |                     |                       |
| Skin disorder                                        | 2 5.38)                         | 0（ 0.08)            | 2.78)                 |
| Total No.of events                                   | 2                               | 1                   | 3                     |

9

Figure 4 Most frequent Grade 3 Events, Onset Date, Study Day

<!-- image -->

Source: Listing AE502SE

## Adverse Events of Special Interest

## Infusion-Related Reactions (IRRs)

Potential AEs related to infusions could be reported by investigators in two ways: as symptoms reported on the symptoms of intolerance to infusion CRF page and/or as AEs on the AE CRF page. Potential symptoms of intolerance to infusions underwent medical review by the Applicant. IRRs from either CRF page are found in Table 33. Overall, 22 patients [57.9%] experienced an IRR in the rituximab + prednisone arm (Table 29).

<div style=\"page-break-after: always\"></div>

IRR symptoms reported in &gt;=5% (2 or more patients) for the Day 1 or Day 15 infusions were: headaches, chills,  high  blood pressure, nausea, asthenia, and pain (Table 24). All IRRs noted on the symptoms of intolerance CRF page by the investigators were Grades 1 or 2.

Table 24

## Reported CRF terms of Intolerance to Rituximab by Visit(Safety PV Population)

|                                 |       |       | ml     |        |
|---------------------------------|-------|-------|--------|--------|
| paeiests Fel M.                 | (20.M | (31.H | 11.10) | 11.041 |
| Dulls Seidachen TY Palpatatlenn |       |       |        | -0     |
|                                 | 0.31  |       |        |        |
|                                 |       | 1.30  |        | 1.1    |
|                                 |       | 2.10  | 2.14)  | 2.641  |

ariisH 2 led ituinb infaie.Her, is a mall us ap. h 0.5

Shue patienso tho Teeeeotepee eparienced

Mocrled thom Lae014e

Table 25

## Summary of Infusion-related Reactions from all Sources by Infusion (Safety PvPopulation）

|         | p 1 Dfim   | Pay l Pafenlm   |       |
|---------|------------|-----------------|-------|
| Tel . C | .4         | T5.             |       |
|         | C21.1      | 日 C. 0000       | 15.54 |

leroeneepes anm

Modteo rom Lat017H

<div style=\"page-break-after: always\"></div>

## Infections:

## Treatment-Related Infections - Safety PV Population

Fourteen patients (36.8%) in the rituximab + prednisone arm experienced 43 treatment-related infections and 15 patients (41.7%) in the prednisone arm experienced 28 treatment-related infections (Table 34).

The most frequent infection PTs (occurring in &gt;=5% in either treatment arm [rituximab + prednisone arm vs. prednisone), were: bronchitis (3 patients [7.9%] vs. 7 patients [19.4%]), urinary tract infection (2 patients [5.3%] vs. 3 patients [8.3%]), fungal infection (2 patients [5.3%] vs. 2 patients [5.6%]), skin bacterial infection (1 patient [2.6%] vs. 3 patients [8.3%]), herpes virus infection (3 patients [7.9%] vs. 0 patients), herpes zoster (2 patients [5.3%] vs. 1 patient [2.8%]), oral herpes (2 patients [5.3%] vs. and 1 patient [2.8%]), and conjunctivitis (2 patients [5.3%] vs. 0 patients).

|                                              | Butuinb . ehlean   |           | AL Paleete   |
|----------------------------------------------|--------------------|-----------|--------------|
| Dfenia e Lafestanies Crinang trart infeetion |                    | 41.7 0.01 | 卫            |
| t iec pm                                     |                    |           |              |
| epintaey                                     |                    |           |              |
| Pefete sa                                    |                    |           |              |
| menerebalGecitis Lasmginis                   |                    |           |              |
| Lnfectim                                     |                    |           |              |
| erast Lnfeetimn viml                         |                    |           |              |

Table 26

<!-- image -->

## Serious Infections - Safety PV Population

In the rituximab + prednisone arm, 3 patients (7.9%) experienced 5 serious infections. In the prednisone arm,  1  patient  (2.8%)  experienced  1  serious  infection.  The  PTs  for  serious  infections  (rituximab  + prednisone arm vs. prednisone) were Pneumocystis jirovecii pneumonia (1 patient in each treatment arm), infective thrombosis (1 patient vs. 0 patients), intervertebral discitis (1 patient vs. 0 patients), lung infection (1 patient vs. 0 patients), and staphylococcal sepsis (1 patient vs. 0 patients).

## Development of anti-drug antibodies and safety observations

Eighteen  of  20  (90%)  ADA  positive  (at  any  time,  including  at  baseline)  PV  patients  experienced  130 treatment-related AEs, and 10/14 (71.4%) ADA negative patients experienced 69 treatment-related AEs. The most frequent SOC in both groups was Injury, poisoning and procedural complications, driven by IRRs that occurred in 14/20 (70.0%) ADA positive patients and 6/14 (42.9%) ADA negative patients. However, among the 14 ADA positive patients with IRRs, there were 7 patients in whom IRRs occurred after ADAs were detected. All IRRs in patients tested for ADA were mild to moderate in severity (Grades 1 or 2). There were no lifethreatening/ fatal IRRs or withdrawals due to IRR in these ADA positive and ADA negative patients.

<div style=\"page-break-after: always\"></div>

Of the 6 patients who were ADA positive at baseline (prior to receiving rituximab), 4 patients experienced IRRs. Of the 14/34 patients (41.2%) who were ADA negative at baseline but developed at least one positive ADA titer during the course of the study, 10 patients experienced an IRR; however in only 3 of them IRR occurred after development of a positive ADA titer (data on file). Thus, among ADA positive patients (4 baseline positives and 3 with treatment-induced ADA), 7/20 patients (35.0%) experienced an IRR after development of a positive ADA titer compared to 6/14 (42.9%) patients who experienced an IRR in the ADA negative group.

Overall, the frequency and nature of treatment-related AEs were similar in ADA positive and ADA negative PV patients and consistent with the known safety profile of rituximab.

## Literature overview

From the in total of 805 publications mentioning PV and rituximab, 34 publications were found relevant that had &gt;10 patients with pemphigus and discussed safety/ efficacy findings regarding the use of rituximab. The rituximab dosage used in these studies was similar as currently proposed for the PV indication in this application. The relevant literature articles refer to approximately 1009  patients, of which 756 patients were treated for PV and 79 for PF. In 174 patients the type of pemphigus was not specified.

Of  the  total  34  publications,  26  publications  reported  good  tolerance,  without  serious  events.  8/34 publications reported fatal cases. In none of these cases, cause of death was attributed to rituximab by the author. Serious infections and IRRs were reported in two and seven patients, respectively in two and four publications,  respectively.  Side  effects  with  rituximab  occurred  mainly  during  the  first  infusions.  The majority of these included mild to moderate IRRs and non-serious infections. Acute complications such as angioedema were rarely reported during rituximab infusion and were well manageable.

## Company's Safety Database

A total of 2667 AEs reported in 736 cases were retrieved from the Roche global safety database with the indication 'Pemphigus' using the search strategy. There were 71 cases which contained no information of a Preferrred Term, which  were also excluded from further analysis. Overall, 323/665 (48.6%) of the cases were considered serious.

In  comparison, 104,227 AEs (reported in 34,021 cases) and 9122 AEs (reported in 2,554 cases) were obtained from this database for the approved AI indications RA and AAV, respectively.

Table 27 Total spontaneous reported AEs distributed by SOCs in the pemphigus indication (only &gt;5% of total AE reports)

| soc                                                  |   No. of AEs | % (From total 2275 AEs)   | Most frequently reported PTs                                                                                                                                                                                                                |
|------------------------------------------------------|--------------|---------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Skin and subcutaneous tissue disorders               |          387 | 17.0%                     | Pemphigus and pemphigoid (N=214), pruritus (N=40), urticaria (N=21),erythema (N=13),rash (N=13),blister (N=11), skin ulcer (N=10), skin lesion (N=8), angioedema (N=7), Stevens-Johnson syndrome (N=4) and toxic epidermal necrolysis (N=2) |
| General disorders and administration site conditions |          330 | 14.5%                     | Fatigue (N=47), drug ineffective (N=38), pyrexia (N=36), pain (N=27), drug effect decreased (N=22), asthenia (N=20),malaise (N=15) and chills (N=11)                                                                                        |
| Investigations                                       |          277 | 12.2%                     | Blood pressure increased (N=58), weight increased (N=41),heart rate decreased (N=30),weight decreased (N=24), heart rate increased (N=16) and oxygen saturation decreased (N=14)                                                            |

<div style=\"page-break-after: always\"></div>

| Infections and infestations                     |   217 | 9.5%   | Nasopharyngitis (N=17), pneumonia (N=16), sepsis (N=12), infection (N=11) and influenza (N=11)   |
|-------------------------------------------------|-------|--------|--------------------------------------------------------------------------------------------------|
| Gastrointestinal disorders                      |   163 | 7.2%   | Nausea (N=23), stomatitis (N=16), vomiting (N=12), diarrhoea (N=11) and dysphagia (N=10).        |
| Respiratory, thoracic and mediastinal disorders |   149 | 6.5%   | Cough (N=24), throat irritation (N=22), dyspnoea (N=17) and oropharyngeal pain (N=16)            |
| Injury, poisoning and procedural complications  |   144 | 6.3%   | Infusion related reaction (N=100)                                                                |
| Nervous system disorders                        |   130 | 5.7%   | Headache (N=33) and dizziness (N=23)                                                             |

Most common reported SOC were skin reactions. The SOC Skin and subcutaneous tissue disorders showed a higher reporting rate (17%) for the pemphigus indication as compared to RA (5.5%) and AAV (5.0%). The most frequently reported AEs (55%) in this SOC were pemphigus and pemphigoid, which actually describes the  underlying  disease.  Six  cases  reported  Stevens-Johnson  Syndrome  (SJS  ,  n  =  4)/  Toxic  E pidermal Necrolysis ( TEN , N=2) which is an important identified risk for rituximab. Of these six cases, four cases had alternative  explanation  or  reported  other  risk  factors  (concomitant  medications  such  as  azathioprine, co-trimoxazole etc.) for the event. There was no case which showed a likely causal association of the event with rituximab.

Furthermore, most common spontaneous reported AEs were IRR, GI disorders, infections and headache. No new safety concerns were identified.

## Serious adverse event/deaths/other significant events

## Deaths

No patients died during the study.

<div style=\"page-break-after: always\"></div>

## Serious Adverse Events (SAE)

## Table 28

Serious Adverse Events With Incidence5% Overall by System Organ Class and Preferred Term (Safety PV Population)

| Boun Popes com   |       |         |
|------------------|-------|---------|
|                  | （21.) |         |
| aadecatls        |       |         |
| T3.              |       | 11010-n |

Events coded as he Sylem Orpan CiuPrelemed Term ofGenerai cisordesand adminitratonsie condtionwVunce dsorder should be prouped with events coded aa Musculouleletal ond connective tissue dsorden/Muecle dsorderwhen inerpreting n

Moot+o trom o+004e

Aaterghs indcate he population n which he SAeoccumedat ahigher tequency GShderenoe in tequencybetween treatment am

<div style=\"page-break-after: always\"></div>

Table 29 Treatment-Related Serious Adverse Events by System Organ Class andPreferred Term(SafetyPv Population)

| etetedtem                       | Pati Foedrinone   |        |          |
|---------------------------------|-------------------|--------|----------|
| PatLenta                        |                   | 22.210 | （        |
| PELE                            |                   | RCRRRE | -t- FECO |
| meenedral esie tis ireecil      | Reeeee            |        |          |
| slratee mteprfoenin             |                   |        | ---9 1   |
| al                              |                   |        | ea-t-isi |
| patiente vish sne or moee rente | 00HO              | 1.1    | 7        |
| elar deerdes p tension .        |                   |        |          |
| Ce C                            |                   |        |          |
| SLegeser A                      | 号18:              | 1      |          |
| oenophegitin                    | 18:               | 1      | 1:1      |
| etily.enoedm ay                 | i-                | Gno    | 1.4      |
| Eractue .                       |                   | 8.081  | 1:       |
|                                 |                   | 8：     | -- 1:    |
| deerdnes phne T.                | 000 8:81          | :      |          |
| Bf ents                         |                   | 8:881  |          |

erigtee see foe eisuadme te ie encoedng k rrim L.1.

Events coded as he System Organ ClassPrefemedTem otGeneral dsordenand administaton sRecondtons/Musde dsorder shouid begrouped with events coded asMusculoskeletal and connecive tissue dsordens/lMuscle disorderwhen interpretingn and %. The patients with heve events in meve 2 System Orpan CiastPrelemed Tem categores are mutually eaclusive Modified from toe005ee

<div style=\"page-break-after: always\"></div>

## Serious Adverse Events by Intensity - PV Population

SAEs were categorized by intensity using CTCAE v4: mild (Grade 1), moderate (Grade 2), severe (Grade 3), and  life-threatening  (Grade  4).  Two  patients  (5.3%)  experienced  6  Grade  3  SAEs  in  the  rituximab  + prednisone  arm  and  6  patients  (16.7%)  experienced  10  Grade  3  SAEs  in  the  prednisone  arm.  In  the rituximab + prednisone arm, Grade 3 events occurred in 1 patient each in the following PTs: arthralgia, myalgia, headache, malaise, nausea, and vertigo. In the prednisone arm, Grade 3 SAEs occurred in 1 patient each  in  the  following  PTs:  myopathy,  lumbar  spinal  stenosis,  osteonecrosis,  tendonitis,  pulmonary embolism,  sciatica,  hypertension,  phlebitis,  pemphigus,  and  chorioretinopathy.  In  the  rituximab  + prednisone arm, 7 Grade 4 SAEs were observed in 2 patients in the following PTs: pulmonary embolism (5.3%),  venous  thrombosis  limb  (2.6%),  infective  thrombosis  (2.6%),  intervertebral  discitis  (2.6%), staphylococcal sepsis (2.6%), and femoral neck fracture (2.6%). In the prednisone arm, 4 Grade 4 SAEs were seen in 3 patients in the following PTs: Pneumocystis jirovecii pneumonia (2.8%), weight increased (5.6%), and Cushing's syndrome (2.8%). There were no Grade 5 SAEs.

Table 30 Grade 3 and 4 SAEs In the Rituximab+Prednisone Arm,PV Safety

| Potlent No.   | EventPT                | Grade   | Investigator's causality assessmentto toprednisone rituximab   | Investigator's causality assesement   | Onset, Study Day   | Outcome, Study Day   |
|---------------|------------------------|---------|----------------------------------------------------------------|---------------------------------------|--------------------|----------------------|
| 026-045       | Pulmonary embolism     |         | Doubtfully rehled                                              |                                       | DBO                | Resolved             |
| 026-045       | Venous thromboab limb  |         | Doubtfully relbted                                             |                                       | D88                | Resolved             |
| 926-050       | Femoral neck fracture  | 4       | Possbly reated                                                 |                                       | D264               | Resolved on D268     |
| 926-050       | Puimonary embolism     | 4       | Possbly relaled                                                |                                       |                    |                      |
| 926-050       | Staphylococcal sepsis  |         | Possbly realed                                                 |                                       |                    |                      |
| 926-050       | Infective thrombosis   |         | Poesibly relled                                                |                                       |                    |                      |
| 926-050       | Intervertebral dinetio |         | Possbly related                                                |                                       |                    |                      |
| 029-068       | Arthralgia\"            | 3       | Posebly related                                                |                                       | D359               | Renolved on D372     |
| 633-075       | Verigo                 |         |                                                                |                                       |                    | Resolved             |
| 633-075       | Nautea                 |         |                                                                |                                       |                    | Resolved             |
| 633-075       | Myalgia                | P       |                                                                |                                       |                    | Resolved             |
| 633-075       | Headache               | 3       |                                                                |                                       |                    | Resolved             |
| 633-075       | Malaise                | 3       |                                                                |                                       | D165               | Retolved on D170     |

This event so ntunimab nfuson-related reaction Idenirled by the MAH

Source:ML22196 CSRLhung AE002SE

<div style=\"page-break-after: always\"></div>

Table 31 Grade 3 and 4 SAEsin the Prednisone Arm,PV Safety

<!-- image -->

| Patient No.   | EventPT                        | Grade   | Inventgator's causality assessmentto prednisone   | Onset, study Day   | Outcome, Study Day   |
|---------------|--------------------------------|---------|---------------------------------------------------|--------------------|----------------------|
| 806-009       | Tendonitis                     | 3       | Lihely related                                    |                    | Resolved on D282     |
| 806-009       | Hypertension                   | 3       | Luely related                                     |                    | Resolved on D282     |
| 806-009       | Osteonecrosis                  | 3       | Litely reloted                                    | D212               | Unresolved           |
| #08-067       | Myopathy                       | 3       | Liely related                                     | D59                | Unresolved           |
| 809-008       | Welght ncreased                | 4       | Lilely related                                    |                    | Unrenolved           |
| 013-007       | Pneumocyatis Proveci pneumonia | 4       | Unrelated                                         | D112               | Resolved on D120     |
| 20-046        | Cushing'e syndrome             |         | Liely reloted                                     | D442               | Resolved n-2months   |
| 20-046        | Weight increased               | 4       | Luely related                                     | D442               | Unresolved           |
| F21-065       | Peychiatric decompensation     | 3       | Lhely related                                     | D133               | Unresolved           |
| 029-002       | Lumbar spinal stenoss          | 3       | Not reported                                      | D246               | Resolved on D288     |
| 029-002       | Sciatca                        | 3       | Unrelated                                         | D246               | Resolved on D288     |
| #29-076       | Pemphigus                      | 3       | Unrelated                                         | D29                | Recolved             |
| 630-078       | Chonioretinopathy              | 3       | Relaled\"                                          | D30                | Reeolved on D39      |
| 644-072       | Pulmonary embolism             | 3       | Related'                                          | D197               | Resolvedon D202      |
| 644-072       | Phlebitis                      |         | Related                                           | D197               | Resolved on D202     |

Reported ao relaled in AE torm and unrelated in SAE form

Souree:ML22196 CSR Lstng AE002SE

Figure 5 Grade 3 and 4 SAEs, Onset Date, Study Days

<!-- image -->

Source: ML22196 CSR Listing AE002SE

## Laboratory findings

Testing of clinical chemistry and haematology parameters was performed locally and was not reported in the study database -though abnormalities could be reported as AEs in the CRF-. Only cases reported were blood sodium abnormal (1 case of each study group), one case of anemia (rituximab group) and one case of lymphopenia (prednisone group). None of them were reported as serious.

## Anti-drug antibodies

The main PV study did not have a prospective plan for immunogenicity assessment as part of the study

<div style=\"page-break-after: always\"></div>

protocol.  Immunogenicity  data  of  Human  Anti-Chimeric  Antibody  [HACA]  was  analysed  as  a  post-hoc evaluation by the Applicant from available stored serum samples. In total, 20/34 (58.8%) patients had at least one positive HACA titre at any time during the study. To be noted, 5 subjects had already HACAs at baseline, which increased after rituximab treatment.

The incidence of HACA is higher than reported for other indications in earlier studies. For comparison, a total of 392/3095 (12.7%) patients with rheumatoid arthritis tested positive for HACA in clinical studies following therapy with MabThera. However, it is noted that comparisons between studies is challenging, given differences in assay specificity/sensitivity. HACA was not associated with an increased risk of IRR or loss of efficacy in the main study. Therefore, no further questions are raised.

Haematology and clinical chemistry data were not systematically reported. Neutropenia is known to be common for rituximab in the treatment of other auto-immune disorders, however, this was not reported in the PV study.

## Safety in special populations

No analyses were made with regards to intrinsic or extrinsic factors.

## Safety related to drug-drug interactions and other interactions

No additional information on potential drug-drug interactions was obtained from Study ML22196.

Therapeutic antibodies such as rituximab are not metabolized via cytochrome P450 and accordingly, the rituximab label (Rituxan USPI/EU SmPC) states that formal drug interaction studies have not been performed with rituximab.  In clinical trials of patients with RA, concomitant administration of MTX or cyclophosphamide did not alter the pharmacokinetics of rituximab.

In patients with chronic lymphoid leukemia, rituximab did not alter systemic exposure to fludarabine or cyclophosphamide. In patients with non-Hodgkin lymphoma, renal toxicity has been seen in patients treated with cisplatin; therefore the combination of cisplatin and rituximab is not an approved treatment regimen.

A population pharmacokinetic analysis of RA patients suggested that co-administration with cyclophosphamide, MTX, or glucocorticoids has no effect on the pharmacokinetics of rituximab. Furthermore, as the elimination of rituximab is mediated by both the specific CD20 -receptor-mediated pathway and the non-specific immunoglobulin G clearance pathway, rituximab is not expected to interact with other drugs through protein binding, effects on cytochrome P450 activity, renal excretion, and/or competition for common drug transporter proteins.

## Use in Pregnancy and Lactation

There was 1 pregnancy in a patient in the rituximab + prednisone arm during the ML22196 study; the patient delivered a healthy baby with no subsequent AEs reported.  Eight pregnancy-related events in patients with pemphigus in the rituximab + prednisone arm were reported in the applicant's global safety database, of which 1 was pregnancy of partner.  No adverse pregnancy outcomes were observed in patients treated with rituximab except in the case of pregnancy of partner, where the baby was preterm and had low birth weight. However, this case contained no perinatal details or details about the patient's partner, which would allow a meaningful assessment.

There are no adequate and well-controlled studies of rituximab in pregnant women.  Post marketing data indicate that B-cell lymphocytopenia generally lasting less than 6 months can occur in infants exposed to rituximab in-utero.  Rituximab was detected postnatally in the serum of infants exposed in-utero.

<div style=\"page-break-after: always\"></div>

Reproduction studies in cynomolgus monkeys at maternal exposures similar to human therapeutic exposures showed no evidence of teratogenic effects as described in the labeling for rituximab (Rituxan USPI/MabThera SmPC).  However, B-cell lymphoid tissue was reduced in the offspring of treated dams.  The B-cell counts returned to normal levels, and immunologic function was restored within 6 months of birth (Rituximab PBRER [Report no. 1073199]).

PV is a serious life-threatening condition that requires treatment.  Rituximab should be used during pregnancy only if the potential benefit to the mother justifies the potential risk to the fetus.

## Discontinuation due to adverse events

## Adverse Events That Led to Withdrawal of Study Treatment - Safety PV Population

AEs leading to protocol withdrawal were collected on the End of Study (EoS) CRF page, and if an SAE, also on  the  SAE  form.  All  AEs  leading  to  protocol  withdrawal  in  this  study  were  SAEs.  In  the  rituximab  + prednisone arm, 1 patient out of 38 patients (2.6%) withdrew from study treatment due to the AE of pregnancy, which was reported as an SAE by the Investigator.

The Applicant identified an instance where there was a discrepancy in the data collected on the EoS page and the SAE form for a PV prednisone patient (19-059) resulting in showing this patient's reason for protocol withdrawal as 'ineffectiveness of treatment' and 7 PV patients in the prednisone arm whose reason for withdrawal was an AE; whereas in tae018se, this patient is counted among the 8 patients in the prednisone arm who had an AE leading to protocol withdrawal. Therefore, in the prednisone arm, 8 patients out of 36 patients (22.2%) withdrew from study treatment due to 10 AEs of which all 10 were SAEs (Table 25). AEs leading to withdrawal in the prednisone arm were largely related to corticosteroid use and included necrosis of the femoral heads, corticosteroid-induced myopathy, Cushing's syndrome, psychiatric decompensation, and chorioretinitis. The listing of any AE leading to protocol withdrawal is lae009se. Narratives for all patients who experienced SAEs are provided.

## Adverse events that led to dose modification

One PV patient in the rituximab + prednisone treatment group had the second rituximab infusion delayed due to bronchitis.

Dose  modifications  of  prednisone  were  not  collected  in  the  study.  Prednisone  doses  could  have  been escalated with relapse or failure to respond. Other than in these situations, doses given that deviated from the protocol can be seen in the listing of protocol deviations (lds004ap).

## Post marketing experience

Rituximab is not marketed in any country for the indication of PV.  No new safety signals were identified in the ML22196 study compared with the overall rituximab safety data in approved AI indications as presented in the PBRER (Report 1073199).

The proven and observed benefit of rituximab in clinical trials and clinical practice far outweighs the known and generally manageable identified risks associated with rituximab treatment.

Since the international birth data (26 November 1997) until 30 September 2016, approximately 5,378,160 patient-market exposures have been estimated for rituximab:

- Hematological malignancies: approximately 4,431,334
- AI indications: Approximately 946,826 (approximately 554,080 unique patients)
- -RA: approximately 717,362 (approximately 386,682 unique patients)
- -Other AI indications: approximately 229,464 (approximately 157,398 unique patients)

<div style=\"page-break-after: always\"></div>

## 2.5.1. Discussion on clinical safety

Overall, the majority of patients in both treatment arms experienced treatment-related AEs, however, there are significant differences in favour of the rituximab arm with regards to SAEs, treatment-related SAEs and withdrawal of study treatment. Looking at AEs occurring &gt;= 10% of patients it is seen that in most SOCs the rituximab+prednisone  arm  fares  better,  which  is  most  likely  explained  by  the  fact  that  exposure  to prednisone was considerable lower in this arm. However, in two SOCs ('injury, poisoning and procedural complications' and 'skin and subcutaneous tissue disorders') rituximab+prednisone arm fares worse than the prednisone arm. This is related to IRR. Following AEs occurred frequently in the rituximab-prednisone arm: IRR, insomnia, Cushing's syndrome, arthralgia, asthenia, persistent depressive order and alopecia. These are all well-known AEs related to rituximab and clearly reflected in the SmPC, except for Cushing's syndrome, which is related to prednisone.

The  use  of  rituximab  in  combination  with  prednisone  did  not  lead  to  an  increase  in  infections.  This  is reassuring. However, the numbers are small and no clear pattern can be observed.

There were no deaths in this study, and overall there were more patients in the prednisone arm who experienced an SAE, however, looking at the number of SAEs there is no difference between the two treatment arms.  Looking at SAEs with an incidence of &gt;=5%, most SAEs are related to musculoskeletal system.  Some  of  these  SAEs,  e.g.  osteoporotic  fracture,  are  related  to  prednisone,  while  other,  e.g. arthralgia, are related to rituximab. The majority of events occurred in only one patient.

## 2.5.2. Conclusions on clinical safety

Overall, the use of rituximab in combination with low-dose prednisone was well-tolerated. No new safety finding were observed during the study, and the observed AEs/SAEs are in line with the well-known and well-characterised safety profile of rituximab.  However an update of section 4.8 of the SmPC was introduced in order to reflect the safety profile observed in patients with PV.

## 2.5.3. PSUR cycle

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

## 2.6. Risk management plan

The CHMP received the following PRAC Advice on the submitted Risk Management Plan:

The PRAC considered that the risk management plan version 19.1 is acceptable. This RMP version 19.1 also includes approved RMP version 17.1 (based on version 16.1 and including relevant updates from version 17.0, EMEA/H/C/000165/II/0149).  In addition changes arising from versions 17.0 (current procedure EMEA/H/C/000165/II/0150), 18.0 (EMEA/H/C/000165/II/0152) and 19.0 (EMEA/H/C/000165/II/0157 and EMEA/H/C/000165/II/0158) have been merged resulting in new version 19.1.

The PRAC endorsed PRAC Rapporteur assessment report is attached.

The CHMP endorsed this advice without changes.

The CHMP endorsed the Risk Management Plan version 19.1 with the following content:

<div style=\"page-break-after: always\"></div>

## Safety concerns

| Summary of safety concerns   | Summary of safety concerns                                                                                                                                                                                                                                                                                                        |
|------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Important identified risks   | • Infusion related reactions • Infections including serious infections • Progressive multifocal leukoencephalopathy • Hepatitis B reactivation • Hypogammaglobulinemia (non-oncology indications)                                                                                                                                 |
| Important potential risks    | • Malignant events (non-oncology indications) • Impact on cardiovascular disease (non-oncology indications) • Relapses (GPA/MPA only) • Off label use in paediatric patients • Off label use of the subcutaneous formulation (NHL/CLL subcutaneous formulations) • Administration route error (NHL/CLL subcutaneous formulations) |
| Missing information          | • Long term use in GPA/MPA patients (GPA/MPA only) • Use in pregnancy and lactation                                                                                                                                                                                                                                               |

The following safety concerns have been removed from the RMP with reference to GVP module V guideline (rev 2):

## Important identified risks (approved via EMEA/000165/II/0144):

- Impaired immunisation response
- Neutropenia (including prolonged neutropenia)
- Stevens-Johnson syndrome / toxic epidermal necrolysis
- Tumour lysis syndrome (NHL/CLL)
- Gastrointestinal perforation (NHL/CLL)
- Local cutaneous reactions (NHL/CLL subcutaneous formulations)

## Important potential risks:

- Prolonged B-cell depletion (EMEA/000165/II/0157, EMEA/000165/II/158)
- Second malignancies (EMEA/000165/II/0144)
- Posterior reversible encephalopathy syndrome (EMEA/000165/II/0144)
- Acute myeloid leukaemia and myelodysplastic syndrome (NHL/CLL) (EMEA/000165/II/0144)
- Increased risk of grade 3-4 and serious blood and lymphatic system adverse events in older patients (&gt;70 years of age) (EMEA/000165/II/0144)

<div style=\"page-break-after: always\"></div>

-Off label use in autoimmune disease (RA &amp; GPA/MPA) (EMEA/000165/II/0152)

## Missing information

- Immunogenicity associated with the subcutaneous formulation (NHL/CLL subcutaneous formulations) (EMEA/000165/II/0157, EMEA/000165/II/158)

## Pharmacovigilance plan

| Study Status                                                                                                                                                                                                                                                                                                                                                                                            | Summary of objectives                                                                                                                                                                                   | Safety concerns addressed                                     | Milestones                                                    | Due dates                                                                              |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|----------------------------------------------------------------------------------------|
| Category 3 - Required additional pharmacovigilance activities                                                                                                                                                                                                                                                                                                                                           | Category 3 - Required additional pharmacovigilance activities                                                                                                                                           | Category 3 - Required additional pharmacovigilance activities | Category 3 - Required additional pharmacovigilance activities | Category 3 - Required additional pharmacovigilance activities                          |
| WA25615/PePRS Phase IIa, international, multicenter, open-label, single-arm study in pediatric GPA/MPA patients Ongoing                                                                                                                                                                                                                                                                                 | Evaluate the safety and tolerability of rituximab in pediatric patients with severe GPA/MPA                                                                                                             | Off-label use in pediatric patients                           | FPFV                                                          | 23 May 2013                                                                            |
| WA25615/PePRS Phase IIa, international, multicenter, open-label, single-arm study in pediatric GPA/MPA patients Ongoing                                                                                                                                                                                                                                                                                 | Evaluate the safety and tolerability of rituximab in pediatric patients with severe GPA/MPA                                                                                                             | Off-label use in pediatric patients                           | LPLV                                                          | May 2018                                                                               |
| WA25615/PePRS Phase IIa, international, multicenter, open-label, single-arm study in pediatric GPA/MPA patients Ongoing                                                                                                                                                                                                                                                                                 | Evaluate the safety and tolerability of rituximab in pediatric patients with severe GPA/MPA                                                                                                             | Off-label use in pediatric patients                           | Study end                                                     | The common closeout date will occur 18 months after the enrollment of the last patient |
| Plasma exchange and glucocorticoid dosing in the treatment of ANCA-associated vasculitis (PEXIVAS)                                                                                                                                                                                                                                                                                                      | Capture long-term safety data in order to further evaluate dose regimen of rituximab in relation to infection's frequency, seriousness and severity                                                     | Infections including serious infections                       | Final CSR                                                     | Expected in April 2019                                                                 |
| Intergroup B-NHL-2010 Open-label, randomized, controlled, parallel-group, multicenter trial to evaluate the pharmacokinetics, pharmacodynamics , safety and efficacy or rituximab add-on to standard chemotherapy in children from 6 months to less than 18 years of age with advanced stage B-cell lymphoma (excluding primary mediastinal B-cell lymphoma), Burkitt and Burkitt-like lymphoma/Leukemi | Evaluate the safety and tolerability of rituximab in pediatric patients with advanced stage B-cell lymphoma (excluding primary mediastinal B-cell lymphoma), Burkitt and Burkitt-like lymphoma/Leukemia | Off-label use in pediatric patients                           | Study Start                                                   | November 2011                                                                          |
| Intergroup B-NHL-2010 Open-label, randomized, controlled, parallel-group, multicenter trial to evaluate the pharmacokinetics, pharmacodynamics , safety and efficacy or rituximab add-on to standard chemotherapy in children from 6 months to less than 18 years of age with advanced stage B-cell lymphoma (excluding primary mediastinal B-cell lymphoma), Burkitt and Burkitt-like lymphoma/Leukemi | Evaluate the safety and tolerability of rituximab in pediatric patients with advanced stage B-cell lymphoma (excluding primary mediastinal B-cell lymphoma), Burkitt and Burkitt-like lymphoma/Leukemia | Off-label use in pediatric patients                           | Study end                                                     | June 2019                                                                              |

<div style=\"page-break-after: always\"></div>

| Study Status                                                                                                                                                                                                                                            | Summary of objectives                                                                                                                                                                                                                               | Safety concerns addressed                                                                                                                                                                                                                                                                                  | Milestones                                                                                                   | Due dates                                                  |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------|------------------------------------------------------------|
| a conducted in accordance with the approved PIP Ongoing                                                                                                                                                                                                 |                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                                                            |                                                                                                              |                                                            |
| An international, open label, randomized controlled trial comparing rituximab with azathioprine as maintenance therapy in relapsing ANCAassociated vasculitis (RITAZAREM)-Pha se III, interventional, randomized, openlabel, comparative trial          | Time to relapse / the primary endpoint is the time to disease relapse (either minor or major relapse) from randomization. Proportion of patients who maintain remission at 24 and 48 months                                                         | Relapses                                                                                                                                                                                                                                                                                                   | Estimated study completion date                                                                              | January 2021                                               |
| Ongoing BE29950 (RIVAS): Prospective, single center, secondary data use, long-term surveillance, noninterventionalP ASS. Ongoing                                                                                                                        | Registry to collect serious adverse event data over 5 years to determine the long-term safety of rituximab for the treatment of GPA/MPA.                                                                                                            | Long term use in GPA/MPA patients                                                                                                                                                                                                                                                                          | Study start                                                                                                  | Q4 2016                                                    |
| Ongoing BE29950 (RIVAS): Prospective, single center, secondary data use, long-term surveillance, noninterventionalP ASS. Ongoing                                                                                                                        | Registry to collect serious adverse event data over 5 years to determine the long-term safety of rituximab for the treatment of GPA/MPA.                                                                                                            | Long term use in GPA/MPA patients                                                                                                                                                                                                                                                                          | Interim analyses                                                                                             | Annual reporting of cumulative data in PBRER               |
| Ongoing BE29950 (RIVAS): Prospective, single center, secondary data use, long-term surveillance, noninterventionalP ASS. Ongoing                                                                                                                        | Registry to collect serious adverse event data over 5 years to determine the long-term safety of rituximab for the treatment of GPA/MPA.                                                                                                            | Long term use in GPA/MPA patients                                                                                                                                                                                                                                                                          | Interim report                                                                                               | 3 year after study start                                   |
| Ongoing BE29950 (RIVAS): Prospective, single center, secondary data use, long-term surveillance, noninterventionalP ASS. Ongoing                                                                                                                        | Registry to collect serious adverse event data over 5 years to determine the long-term safety of rituximab for the treatment of GPA/MPA.                                                                                                            | Long term use in GPA/MPA patients                                                                                                                                                                                                                                                                          | Final report                                                                                                 | 5 year after study start                                   |
| Category 4: Stated additional pharmacovigilance activities                                                                                                                                                                                              | Category 4: Stated additional pharmacovigilance activities                                                                                                                                                                                          | Category 4: Stated additional pharmacovigilance activities                                                                                                                                                                                                                                                 | Category 4: Stated additional pharmacovigilance activities                                                   | Category 4: Stated additional pharmacovigilance activities |
| WA27893/RaAVeR: A multi-centre (US-based), prospective, observational study designed to follow 100 rituximab treated patients with granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA) for a maximum of 4 years. Completed NI-PASS | Primary objective of this study is to characterize the long-term safety of rituximab in the treatment of GPA or MPA. Secondary objective of this study is to collect data on the safety of re-treatment with rituximab in patients with GPA or MPA. | Infusion-related reactions (All Indications) Infections, including serious infections (All Indications) Hepatitis B reactivation (All Indications) Malignant events (RA and GPA/MPA) Impact on cardiovascular disease (RA and GPA/MPA) Relapses (GPA/MPA) Use in pregnancy and lactation (All Indications) | First patient in Last patient in Last Patient Last Visit Interim Clinical Study Report Final Report expected | 20 Jun 2012 19 May 2013 19 May 2017 April 2016 April 2018  |
| Anti Rheumatic Therapy in Sweden                                                                                                                                                                                                                        | To initiate a nationwide post-marketing inception                                                                                                                                                                                                   | Infections, including serious infections (All                                                                                                                                                                                                                                                              | First patient in                                                                                             | Q2 2007                                                    |

<div style=\"page-break-after: always\"></div>

| Study Status                                                                                                       | Summary of objectives                                                                                                                                                                                                               | Safety concerns addressed                                                                                                                                                                       | Milestones                                                         | Due dates                                                    |
|--------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------|--------------------------------------------------------------|
| (ARTIS)- Nation-wide safety monitoring of MabThera treatment in patients with rheumatic Diseases in Sweden Ongoing | cohort of patients treated with rituximab (MabThera), including all patients with rheumatoid arthritis (RA)                                                                                                                         | Indications) Malignant events (RA and GPA/MPA) Impact on cardiovascular disease (RA and GPA/MPA) Use in pregnancy and lactation (All Indications)                                               | 3-year report 5-year report Final report expected                  | Dec 2011 Dec 2013 Annual updates in PBRERs                   |
| British Society of Rheumatology Biologics Registry (BSRBR) Ongoing NI-PASS                                         | Evaluate the safety profile of rituximab in Rheumatoid arthritis patients in comparison to RA patients treated with anti- tumor necrosis factor (TNF)α agents and standard disease-modifying anti rheumatic drugs (DMARD) medicines | Infections, including serious infections (All Indications) Malignant events (RA and GPA/MPA) Impact on cardiovascular disease (RA and GPA/MPA) Use in pregnancy and lactation (All Indications) | First patient in 3-year report 5-year report Final report expected | Q2 2008 August 2013 Q1 2015 Q3 2019 Annual updates in PBRERs |
| RABBIT(Rheumatoi d arthritis observation of biologic therapy) Ongoing NI-PASS                                      | Evaluate long term effectiveness of treatment with biological agents with regard to treatment continuation and clinical outcomes, and to study the long term safety of treatment with biologic therapy in RA.                       | Infections, including serious infections (All Indications) Malignant events (RA and GPA/MPA) Impact on cardiovascular disease (RA and GPA/MPA) Use in pregnancy and lactation (All Indications) | First Patient In Planned submission of final data                  | Q2 2007 Q4 2022 Annual updates in PBRERs                     |

## Risk minimisation measures

| Safety concern             | Risk minimisation measures                                                                                                                                   | Pharmacovigilance activities                                                                  |
|----------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------|
| Infusion related reactions | SmPC section 4.4 & 4.8 Other risk minimisation measures: Medicinal product subject to restricted medical prescription Additional risk minimisation measures: | Routine pharmacovigilance activities Additional pharmacovigilance activities: RAVeR (WA27893) |

<div style=\"page-break-after: always\"></div>

| Safety concern                             | Risk minimisation measures                                                                                                                                                                                                                                                             | Pharmacovigilance activities                                                                                                                                                                                                                                                        |
|--------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                            | Educational outreaches (RA and GPA/MPA only)                                                                                                                                                                                                                                           |                                                                                                                                                                                                                                                                                     |
| Infections including serious infections    | SmPC sections 4.4 & 4.8 Other risk minimisation measures: Medicinal product subject to restricted medical prescription Additional risk minimisation measures: Patient alert card (non-oncology indications only) Educational material for HCPs and patients (non-oncology indications  | Routine pharmacovigilance activities Additional pharmacovigilance activities: Evaluate results from PEXIVAS study in GPA/MPA Study RAVeR (WA27893) Anti-rheumatic Therapy in Sweden (ARTIS) British Society of Rheumatology Biologics Registry (BSRBR) RABBIT (Rheumatoid arthritis |
| Progressive multifocal leukoencephalopathy | SmPC sections 4.4 Other risk minimisation measures: Medicinal product subject to restricted medical prescription Additional risk minimisation measures: Patients alert card (non-oncology indications only) Educational material for HCPs and patients (non-oncology indications only) | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: Guided questionnaires                                                                                                                                                                 |
| Hepatitis B reactivation                   | SmPC section 4.4 Other risk minimisation measures: Medicinal product subject to restricted medical prescription                                                                                                                                                                        | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: Guided questionnaires Additional pharmacovigilance activities: Study RAVeR (WA27893)                                                                                                  |

<div style=\"page-break-after: always\"></div>

| Safety concern                                              | Risk minimisation measures                                                                                             | Pharmacovigilance activities                                                                                                                                                                                                                                          |
|-------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Hypogammaglubulinemia (non-oncology indications)            | SmPC sections 4.4 & 4.8 Other risk minimisation measures: Medicinal product subject to restricted medical prescription | Routine pharmacovigilance activities                                                                                                                                                                                                                                  |
| Malignant events (non-oncology indications)                 | SmPC section 4.4 Other risk minimisation measures: Medicinal product subject to restricted medical prescription        | Routine pharmacovigilance activities Additional pharmacovigilance activities: Study RaVeR (WA27893) Anti-rheumatic Therapy in Sweden (ARTIS) British Society of Rheumatology Biologics Registry (BSRBR)                                                               |
| Impact on cardiovascular disease (non-oncology indications) | SmPC section 4.4 Other risk minimisation measures: Medicinal product subject to restricted medical prescription        | Routine pharmacovigilance activities Additional pharmacovigilance activities: Study RaVeR (WA27893) Anti-rheumatic Therapy in Sweden (ARTIS) British Society of Rheumatology Biologics Registry (BSRBR) RABBIT (Rheumatoid arthritis observation of biologic therapy) |
| Relapses (GPA/MPA only)                                     | SmPC section 5.1 Other risk minimisation measures: Medicinal product subject to restricted medical prescription        | Routine pharmacovigilance activities Additional pharmacovigilance activities: Observation and evaluation of data from ongoing studies on maintenance therapy (MAINRITSAN II and RITAZAREM). Study RaVeR (WA27893)                                                     |

<div style=\"page-break-after: always\"></div>

| Safety concern                                                                    | Risk minimisation measures                                                                                                                                                                       | Pharmacovigilance activities                                                                                                                                                                                                                                                                                                                             |
|-----------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Off label use in paediatric patients                                              | SmPC sections 4.1 & 4.2 Other risk minimisation measures: Medicinal product subject to restricted medical prescription                                                                           | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: Guided questionnaires Additional pharmacovigilance activities: Study WA25615 (an interventional PASS) Intergroup trial (Inter-BNHL 2010) for children or adolescents with B-cell NHL or B-AL in accordance with the approved Paediatric Investigation Plan |
| Off label use of the subcutaneous formulation (NHL/CLL subcutaneous formulations) | SmPC sections 4.1, 4.2 & 4.4 Other risk minimisation measures: Medicinal product subject to restricted medical prescription Additional risk minimization measures: Educational material for HCPs | Routine pharmacovigilance activities                                                                                                                                                                                                                                                                                                                     |
| Administration route error (NHL/CLL subcutaneous formulations                     | SmPC section 4.2 Other risk minimisation measures: Medicinal product subject to restricted medical prescription Additional risk minimization measures: Educational material for HCPs             | Routine pharmacovigilance activities                                                                                                                                                                                                                                                                                                                     |
| Use in pregnancy and lactation                                                    | SmPC section 4.6 Other risk minimisation measures: Medicinal product subject to restricted                                                                                                       | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: Standard pregnancy report form for follow-up.                                                                                                                                                                                                              |

<div style=\"page-break-after: always\"></div>

| Safety concern                              | Risk minimisation measures                                                                     | Pharmacovigilance activities                                                                                                                                                                                                     |
|---------------------------------------------|------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                             | medical prescription                                                                           | Additional pharmacovigilance activities: Study RaVeR (WA27893) Anti-rheumatic Therapy in Sweden (ARTIS) British Society of Rheumatology Biologics Registry (BSRBR) RABBIT (Rheumatoid arthritis observation of biologic therapy) |
| Long term use in GPA/MPA patients (GPA/MPA) | Other risk minimisation measures: Medicinal product subject to restricted medical prescription | Routine pharmacovigilance activities Additional pharmacovigilance activities: WA27893 (RaVeR) RIVAS (BE29950) registry                                                                                                           |

## 2.7. Update of the Product information

As a consequence of this new indication, sections 4.1, 4.2, 4.3, 4.4, 4.5, 4.8 and 5.1 of the SmPC have been updated.The Package Leaflet has been updated accordingly.

## 2.7.1. User consultation

No justification for not performing a full user consultation with target patient groups on the package leaflet has been submitted by the MAH. However, the changes to the package leaflet are minimal and do not require user consultation with target patient groups.

## 3. Benefit-Risk Balance

## 3.1. Therapeutic Context

The MAH seeks regulatory approval for rituximab in the following indication:

Rituximab is indicated for the treatment of adult patients with moderate to severe pemphigus vulgaris.

## 3.1.1. Disease or condition

Pemphigus vulgaris (PV) is a rare, serious and life-threatening autoimmune blistering disease affecting the mucosa and skin, and there is a high unmet medical need for safer and more effective treatment options. Due to the rarity of pemphigus, few prospective clinical trials are available and these are limited by the low numbers of patients studied and treatment arms that do not demonstrate statistically significant differences.

<div style=\"page-break-after: always\"></div>

## 3.1.2. Available therapies and unmet medical need

Corticosteroids and, in some European countries, azathioprine are the only EU-approved treatments for patients with PV.  Systemic corticosteroids have been the mainstay of treatment for pemphigus patients since the 1950s based on limited and uncontrolled clinical data.  Similarly, the use of adjuvant immunosuppressant therapy, such as azathioprine, which has been approved alone and in combination with systemic corticosteroids, for the treatment of PV in the European Union for over 15 years, has been established in treatment guidelines in Europe despite the scarcity of well-designed randomized controlled studies, and evidence that adjuvant therapies have only a minimal steroid-sparing effect.

Based on the literature, chronic and/or high dose corticosteroid therapy alone results in an estimated remission rate of &lt; 30%.  Remission may be short lived. Serious and sometimes fatal AEs, resulting from immunosuppression due to long-term use of steroids, may occur.  Despite widespread use, there is no consensus on whether unapproved steroid-sparing agents are beneficial due to the scarcity of well-designed randomized controlled studies.  PV remains a serious life-threatening disease and given the unsatisfactory safety and efficacy profile of the existing approved therapies (corticosteroids and azathioprine), a major unmet medical need exists for safer and more effective novel, targeted mechanism-based treatment options for moderately to severely active PV.

## 3.1.3. Main clinical studies

The MAH has provided study MM22196, an open-label, phase III, multicentre, and randomised study in patients with newly diagnosed moderate to severe pemphigus. The study was run by academia (Rouen University Hospital, France). The MAH had no role in study design, conduct, data collection or publication of results. The database was transferred from the Sponsor to the MAH in December 2016 after database lock.

## 3.2. Favourable effects

The study met its primary endpoint showing a statistically significant and clinically relevant difference between the treatment arms in favour of rituximab. In total 89.5% (34/38) of the patients in the rituximab+prednisone arm had CR off prednisone therapy for at least 2 months at month 24. In comparison only 27.8% (10/36) of the patients in the prednisone arm experienced CR off prednisone for at least 2 months at month 24. Looking at CR off prednisone for at least 3 months at month 24 (the original primary endpoint) similar results are observed. This is reassuring.

With regard to the secondary endpoints it was shown that the number of patients who had at least one severe/moderate relapse at month 24 was considerable lower in the rituximab arm (23.7% vs. 50.0%). Number of patients with CR at month 24 on minimal prednisone treatment was significantly higher in the rituximab arm. Total cumulative dose prednisone at month 24 was significantly lower in the rituximab arm. Finally, the duration of CRoff prednisone at month 24 in responders was considerable longer in the rituximab arm. Overall, all secondary endpoints support the findings in relation to the primary endpoint.

Considering the QoL results, the sponsor had used Skindex-France and DLQI. No relevant differences are observed, however, considering the open-label nature of the study, no major emphasis is put on this results.

## 3.3. Uncertainties and limitations about favourable effects

The use of rituximab in combination with prednisone was studied in patients newly diagnosed with pemphigus vulgaris, but the claimed indication includes patients with established pemphigus vulgaris (relapsed setting). The MAH has justified the extrapolation, which includes a PK, PD, efficacy and safety discussion, by reasoning as well as by the already provided supporting evidence. There are nevertheless uncertainties due to the limitations of the data provided in the established disease.

<div style=\"page-break-after: always\"></div>

## 3.4. Unfavourable effects

Overall, the majority of patients in both treatment arms experienced treatment-related AEs, however, there are significant differences in favour of the rituximab arm with regards to SAEs, treatment-related SAEs and withdrawal of study treatment. Looking at AEs occurring &gt;= 10% of patients it is seen that in most SOCs the rituximab+prednisone arm fares better, which is most likely explained by the fact that exposure to prednisone was considerable lower in this arm. However, in two SOCs ('injury, poisoning and procedural complications' and 'skin and subcutaneous tissue disorders') rituximab+prednisone arm fares worse than the prednisone arm. This is related to IRR. Following AEs occurred frequently in the rituximab-prednisone arm: Infusion Related Reactions (IRR), insomnia, Cushing's syndrome, arthralgia, asthenia, persistent depressive order and alopecia. These are all well-known AEs related to rituximab and clearly reflected in the SmPC, except for Cushing's syndrome, which is related to prednisone. The use of rituximab in combination with prednisone did not lead to an increase in infections. This is reassuring. The numbers are small and no clear pattern can be observed.

## 3.5. Uncertainties and limitations about unfavourable effects

There are no uncertainties or limitations about the unfavourable effects.

## 3.6. Effects Table

| Effect                | Short description     | Short description                               | Unit                 | Treatme nt           | Control              | Uncertainties / Strength of evidence                                                  | References                                                                            | References           |
|-----------------------|-----------------------|-------------------------------------------------|----------------------|----------------------|----------------------|---------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------|----------------------|
| Favourable Effects    | Favourable Effects    | Favourable Effects                              | Favourable Effects   | Favourable Effects   | Favourable Effects   | Favourable Effects                                                                    | Favourable Effects                                                                    | Favourable Effects   |
| CRoff at Month 24     | CRoff at Month 24     | Clinical remission off- CS therapy for 2 months | %                    | 90                   | 28                   | Probable bias by open-label design (CI not reported)                                  | Probable bias by open-label design (CI not reported)                                  | 1                    |
| Relapses              | Relapses              | Patients with relapses                          | %                    | 24                   | 50                   | idem                                                                                  | idem                                                                                  | 1                    |
| CR min.               | CR min.               | Clinical remission on minimal CS therapy        | %                    | 90                   | 33                   | idem                                                                                  | idem                                                                                  | 1                    |
| Remission duration    | Remission duration    | Median duration of remission in patients CRoff  | days                 | 490                  | 125                  | idem                                                                                  | idem                                                                                  | 1                    |
| Prednisone            | Prednisone            | Median cumulative CS dose                       | mg                   | 5800                 | 20.520               | idem                                                                                  | idem                                                                                  | 1                    |
| CRoff maintained      | CRoff maintained      | CRoff maintained at month 36                    | %                    | 94                   | 60                   | Influenced by differential drop-out                                                   | Influenced by differential drop-out                                                   | 1                    |
| Unfavourable Effects  | Unfavourable Effects  | Unfavourable Effects                            | Unfavourable Effects | Unfavourable Effects | Unfavourable Effects | Unfavourable Effects                                                                  | Unfavourable Effects                                                                  | Unfavourable Effects |
| AEs                   | AEs                   | Number of subjects with one or more AEs         | %                    | 32/38 (84.2)         | 30/36 (83.3)         | For non-serious AEs, only treatment-related AEs were reported: risk of underreporting | For non-serious AEs, only treatment-related AEs were reported: risk of underreporting | 1                    |
| SAE                   | SAE                   | Number of subjects with one or more SAEs        | n/N, %               | 11/38 (28.9)         | 16/36 (44.4)         | Potential bias open-label design over-estimation for CS treatment                     | Potential bias open-label design over-estimation for CS treatment                     | 1                    |
| Withdrawal due to AEs | Withdrawal due to AEs | Number of subjects withdrawn because of         | n/N, %               | 1/38 (2.6)           | 8/36 (22.2)          | Potential bias open-label design, over-estimation for CS treatment                    | Potential bias open-label design, over-estimation for CS treatment                    | 1                    |

<div style=\"page-break-after: always\"></div>

| Effect                    | Short description                              | Unit   | Treatme nt   | Control      | Uncertainties / Strength of evidence                                       | References   | References   |
|---------------------------|------------------------------------------------|--------|--------------|--------------|----------------------------------------------------------------------------|--------------|--------------|
|                           | SAE                                            |        |              |              |                                                                            |              |              |
| IRR                       | Infusion related reactions (during any course) | n/N, % | 22/38 (57.9) | NA           | IRR were only scored for rituximab (IV), since prednisone was given orally | 1            |              |
| Infections                |                                                | n/N, % | 14/38 (36.8) | 15/36 (41.7) |                                                                            | 1            |              |
| Serious infections        |                                                | n/N, % | 3/38 (7.9)   | 1/36 (2.8)   |                                                                            | 1            |              |
| Myopathy/ muscle disorder |                                                | n/N, % | 1/38 [2.6]   | 8/36 (22.2)  |                                                                            | 1            |              |
| Weight increased          |                                                | n/N, % | 3/38 (7.9)   | 9/36 (25)    |                                                                            | 1            |              |
| Hyperglycae mia           |                                                | n/N, % | 0            | 4/36 (11.1)  |                                                                            | 1            |              |
| Type II diabetes          |                                                | n/N, % | 1/38 (2.6)   | 4/36 (11.1)  |                                                                            | 1            |              |
| Insomnia                  |                                                |        | 8/38 (21.1)  | 11/36 (30.6) |                                                                            | 1            |              |
| Agitation                 |                                                | n/N, % | 1/38 (2.6)   | 6/36 (16.7)  |                                                                            | 1            |              |
| Cataract                  |                                                | n/N, % | 0            | 5/36 (13.8)  |                                                                            | 1            |              |

## 3.7. Discussion on the benefit-risk assessment

## 3.7.1. Importance of favourable and unfavourable effects

High-dose CS is effective in controlling the disease, but long-term use is associated with severe and serious adverse events. Thus, CS sparing treatment options are highly needed. The addition of rituximab to prednisone leads to clinically meaningful decrease in prednisone use. This is highly valued from both a patient and clinicians perspective. The safety profile of this combination is acceptable, with only IRRs standing out. However, IRRs are well-known in relation to the use of rituximab. Clinicians are familiar with this AE and it is manageable in the clinical setting.

## 3.7.2. Balance of benefits and risks

The benefit-risk balance is positive in newly diagnosed patients and patient with established disease. However there are limitations in the data provided for the patients with established disease.

The CHMP considered that additional data are necessary to confirm the benefit of Mabthera in the subgroup of patients with established disease. The ongoing study in the relapsed setting, study WA29330 (PEMPHIX) will provide additional key information on the benefits and risks of Mabthera in these patients. The recruitment is completed and the preliminary and final analyses of this study should be provided post-approval.

## 3.8. Conclusions

The overall B/R is positive.

The CHMP considers the following measures to address issues related to efficacy and safety:

<div style=\"page-break-after: always\"></div>

The ongoing study in the relapsed setting, study WA29330 (PEMPHIX) will provide additional key information on the benefits and risks of Mabthera in patients with established disease. The recruitment is completed and the preliminary and final analyses of this study should be provided post-approval.

## 4. Recommendations

## Outcome

Based on the review of the submitted data, the CHMP considers the following variation acceptable and therefore recommends the variation to the terms of the Marketing Authorisation, concerning the following change:

| Variation accepted   | Variation accepted                                                                                                             | Type    | Annexes affected   |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a              | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I and IIIB         |

Extension of indication to include the treatment of patients with moderate to severe pemphigus vulgaris (PV) for MabThera; as a consequence, sections 4.1, 4.2, 4.3, 4.4, 4.8 and 5.1 of the SmPC are updated. The MAH provided data from a phase III, randomized, controlled, multicenter, open-label study (Study ML22196) evaluating rituximab treatment plus short-term, low dose prednisone treatment compared to long-term, standard dose prednisone treatment as first-line treatment in patients with moderate to severe pemphigus. The Package leaflet is updated accordingly. Minor corrections are also proposed for the sake of accuracy and clarity. An updated RMP (v19.1) was agreed. The annex II is updated to include submission of results of the ongoing PEMPHIX clinical study.

The variation leads to amendments to the Summary of Product Characteristics and Package Leaflet, the annex II and to the Risk Management Plan (RMP).

## Conditions and requirements of the marketing authorisation

## Periodic Safety Update Reports

The marketing authorisation holder shall submit periodic safety update reports for this product in accordance with the requirements set out in the list of Union reference dates (EURD list) ) provided for under Article 107c(7) of Directive 2001/83/EC and published on the European medicines web-portal.

## Conditions or restrictions with regard to the safe and effective use of the medicinal product

## Obligation to conduct post-authorisation measures

The MAH shall complete, within the stated timeframe, the below measures:

| Description                                                                                                                                                                                                                                                                                                                                                                       | Due date                                            |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------|
| Post-authorisation efficacy study (PAES): In order to further investigate the efficacy of Mabthera in the subgroup of patients with established PV as well as to further characterise its long term efficacy and safety on disease progression, the MAH should submit the preliminary study and the final study report of the ongoing randomised phase 3 study (PEMPHIX WA29330). | by Q4 2019 (preliminary CSR) by Q4 2020 (final CSR) |

<div style=\"page-break-after: always\"></div>

## 5. EPAR changes

The EPAR will be updated following Commission Decision for this variation. In particular the EPAR module 8 \" steps after the authorisation \" will be updated as follows:

## Scope

Extension of indication to include the treatment of patients with moderate to severe pemphigus vulgaris (PV) for MabThera; as a consequence, sections 4.1, 4.2, 4.3, 4.4, 4.8 and 5.1 of the SmPC are updated. The MAH provided data from a phase III, randomized, controlled, multicenter, open-label study (Study ML22196) evaluating rituximab treatment plus short-term, low dose prednisone treatment compared to long-term, standard dose prednisone treatment as first-line treatment in patients with moderate to severe pemphigus. The Package leaflet is updated accordingly. Minor corrections are also proposed for the sake of accuracy and clarity. An updated RMP (v19.1) was agreed. The annex II is updated to include submission of results of the ongoing PEMPHIX clinical study.

## Summary

Please refer to Scientific Discussion MabThera-H-C-165-II-150.